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ABSTRACT 
 
Kristen Renee Moore: Reproductive Tract Infections and Uterine Fibroids 
(Under the direction of Jennifer S. Smith and Donna D. Baird) 
 
 For decades, it has been hypothesized that reproductive tract infections (RTIs) are 
risk factors for uterine fibroids. However, only two recent studies have been conducted. We 
aimed to investigate the relationship between RTIs and fibroids in a large study using 
ultrasound screening for fibroids. We used cross-sectional enrollment data from African-
American women ages 23-34 years with no previous fibroid diagnosis. For Aim 1, RTI 
history was measured by self-report. For Aim 2 we used serology, an immunological 
measure of past exposure with a focus on herpes simplex virus type 2 (HSV-2) because prior 
published data have suggested a possible association, and serology for HSV-2 is much more 
accurate than self-report. For both aims, fibroid status was measured by standardized 
ultrasound. Secondary fibroid outcomes were size, number, and total volume. Age- and 
multivariable-adjusted logistic regression were used to estimate odds ratios (ORs).  
 In total, 1,656 women were included; 22% had fibroids. Self-reported bacterial 
vaginosis (BV) was associated with a 21% increased odds of fibroids [aOR 1.21, 95% 
confidence interval (CI) 0.93-1.58]. Self-reported chlamydia infection and pelvic 
inflammatory disease were associated with a 38% (aOR 0.62, 95% CI 0.40-0.97) and a 46% 
(aOR 0.54, 95% CI 0.25-1.17) reduced odds of having two or more fibroids, respectively. 
Those with a previous self-reported BV diagnosis had a 47% increased odds of having 2 or 
more fibroids (aOR 1.47, 95% CI 0.98-2.21) and a 41% increased odds of having a larger 
iv 
total fibroid volume (aOR 1.41, 95% CI 0.98-2.04). There was no significant association 
between HSV-2 seropositivity and fibroid presence (multivariable-adjusted OR: 0.94 95% 
CI: 0.73, 1.20); nor were there any associations with size of largest fibroid, number of 
fibroids, or total fibroid volume. Our study was the first to investigate the association of 
fibroids with HSV-2 exposure assessed serologically. In addition, it was the first to explore 
the relationship between self-reported RTIs and fibroid size, number, and total volume. There 
appeared to be no strong associations between self-reported RTIs or serologically-measured 
HSV-2 seropositivity and the presence of fibroids.  
v 
To my loving husband and beautiful children who motivated me to press on. To my family 
and friends who supported me and never gave up on me; especially my parents and parents-
in-love who stepped in when we needed them most. To my awesome nanny Martha who 
relieved a lot of stress and loved on my children during a very busy time. Most of all, to my 
heavenly Father, Jesus Christ and Holy Spirit, who proved faithful through it all. 
vi 
ACKNOWLEDGEMENTS 
 
 I would like to thank Dr. Donna Baird whose incredible mentorship, wisdom and 
caring spirit guided me through. She also allowed me to use data from her awesome study 
which enabled me to conduct the research for this project. I am extremely grateful for Dr. 
Jennifer Smith for believing in me and providing sound advice and expertise for this project 
along with the rest of my dissertation committee, Drs. Victor Schoenbach, Stephen Cole and 
Dirk Dittmer.  
I would also like to acknowledge Dr. Trevor Archer and the National Institute for 
Environmental Health Sciences (NIEHS) for granting me a fellowship to conduct my 
dissertation research and use their facilities and equipment. I would also like to thank Dr. 
Dale Sandler for approving my proposal for the herpes simplex virus-2 serological tests and 
the whole Epidemiology Department at NIEHS for all of their support. 
I would like to thank the staff at Social and Scientific Systems that conducted the 
field work for the Study of Environment Lifestyle and Fibroids (SELF) and helped to 
facilitate the serology testing and data management, in particular, Dr. Christie Barker-
Cummings, Deborah Cousins, Susan Baker, and Anna Jones. I would also like to thank Dr. 
Charlotte Gaydos and Katherine Schlusser at John’s Hopkins for supervising and conducting 
the serology tests for this project, respectively. 
vii 
TABLE OF CONTENTS 
LIST OF TABLES ................................................................................................................... ix 
LIST OF FIGURES ................................................................................................................. xi 
LIST OF ABBREVIATIONS ................................................................................................. xii 
CHAPTER 1: STATEMENT OF SPECIFIC AIMS ................................................................ 1 
CHAPTER 2: BACKGROUND AND SIGNIFICANCE......................................................... 4 
2.1 Uterine Fibroids (myomas or leiomyomas) .............................................................. 4 
2.2 African-American Heritage and Fibroids .................................................................. 7 
2.3 Infection and Fibroids ............................................................................................... 8 
2.4 Reproductive Tract Infections ................................................................................. 12 
2.5 Biological Mechanisms of Tumorigenesis Following Infection ............................. 18 
CHAPTER 3: RESEARCH DESIGN AND METHODS ....................................................... 21 
3.1 Overview ................................................................................................................. 21 
3.2 Study Participants and Data Collection ................................................................... 21 
3.3 Outcome Assessment .............................................................................................. 22 
3.4 Exposure Assessment .............................................................................................. 24 
3.5 Covariates ................................................................................................................ 24 
3.6 Statistical Analyses ................................................................................................. 24 
CHAPTER 4: SELF-REPORTED REPRODUCTIVE TRACT                                           
INFECTIONS AND ULTRASOUND DIAGNOSED UTERINE                                       
FIBROIDS IN AFRICAN-AMERICAN WOMEN ............................................................... 28 
4.1 Introduction ............................................................................................................. 28 
4.2 Methods ................................................................................................................... 30 
viii 
4.3 Results ..................................................................................................................... 36 
4.4 Discussion ............................................................................................................... 37 
4.5 Conclusions ............................................................................................................. 39 
CHAPTER 5: HERPES SIMPLEX VIRUS-2 SEROPREVALENCE AND                       
ULTRASOUND DIAGNOSED UTERINE FIBROIDS IN A LARGE                        
POPULATION OF YOUNG AFRICAN-AMERICAN WOMEN ........................................ 43 
5.1 Introduction ............................................................................................................. 43 
5.2 Methods ................................................................................................................... 46 
5.3 Results ..................................................................................................................... 51 
5.4 Discussion ............................................................................................................... 52 
CHAPTER 6: CONCLUSIONS ............................................................................................. 62 
6.1 Limitations .............................................................................................................. 62 
6.2 Strengths .................................................................................................................. 68 
6.3 Public Health Implications ...................................................................................... 68 
6.4 Future Research ....................................................................................................... 69 
APPENDIX 1: DIRECTED ACYCLIC GRAPH ................................................................... 70 
APPENDIX 2: CHAPTER 2 SUPPLEMENTAL TABLES .................................................. 71 
REFERENCES ....................................................................................................................... 76 
  
ix 
LIST OF TABLES 
Table 1. Two Recent Studies on Reproductive Tract Infections and Fibroids ....................... 11 
Table 2. Detectable Odds Ratio with 80% Power ................................................................... 27 
Table 3. Distribution of Covariates by Self-Reported Reproductive Tract                                 
Infection Status ....................................................................................................................... 40 
Table 4. Adjusted Odds Ratios for Fibroids According to Self-Reported                                     
History of Reproductive Tract Infections ............................................................................... 41 
Table 5. Herpes Simplex Virus Type 2 Serostatus, Stratified by Selected                                   
Enrollment Characteristics of 1,658 23-34 Year-Old African-American                                     
Women in the Study of Environment Lifestyle and Fibroids, Detroit                                   
Metropolitan Area, Michigan, 2010-2012 .............................................................................. 56 
Table 6. Herpes Simplex Virus Type 2 Serostatus in Relation to Fibroids                                     
among 1,658 23-34 Year-Old African-American Women in the Study of                            
Environment, Lifestyle and Fibroids, Detroit, MI Metropolitan Area,                                             
2010-2012: Odds Ratios and 95% Confidence Intervals ........................................................ 58 
Table 7. Symptomatic and Asymptomatic Serologically-Detected Herpes                                    
Simplex Virus Type 2 in Relation to Fibroids among 1,658 23-34 Year-Old                                
African-American Women in the Study of Environment, Lifestyle and                                           
Fibroids, Detroit, Michigan Metropolitan Area, 2010-2012: Odds Ratios                                     
and 95% Confidence Intervals ................................................................................................ 59 
Table 8. Sensitivity Analyses of the Association of Fibroids with Herpes                                       
Simplex Virus Type 2 Serostatus among 1,658 23-34 Year-Old African-                                  
American Women in the Study of Environment, Lifestyle and Fibroids,                                      
Detroit, Michigan Metropolitan Area, 2010-2012: Odds Ratios and 95%                             
Confidence Intervals ............................................................................................................... 60 
Table 9. Effect of Potential Selection Bias Due to Exclusion of Women                                   
Previously Diagnosed with Fibroids. Crude Odds Ratios for Fibroids                                     
According to HSV-2 Serostatus assuming Varying HSV-2 Seroprevalence                                          
among an estimated 156 Women with Fibroids Excluded from Entry into SELF. ................ 67 
Supplemental Table 1. Age-Adjusted Correlation Coefficients among                                     
Self-Reported Reproductive Tract Infections ......................................................................... 71 
Supplemental Table 2. Percent Distributions of Covariates by Self-Reported                       
Reproductive Tract Infection Status ....................................................................................... 72 
Supplemental Table 3. Years since First Diagnosis of Reproductive Tract                              
Infections................................................................................................................................. 74 
x 
Supplemental Table 4. Adjusted Odds Ratios for Fibroids According to                                      
Self-Reported History of Number of Different Reproductive Tract Infections                               
and Number of Diagnoses for Each Infection ......................................................................... 75 
  
xi 
LIST OF FIGURES 
Figure 1. Theorized Mechanism for Infection and Fibroids ................................................... 20 
Figure 2. Adjusted Odds Ratios for Size of the Largest Fibroid, Number of                               
Fibroids and Total Fibroid Volume According to Self-Reported History of                         
Reproductive Tract Infections ................................................................................................. 42 
Figure 3. Size of largest fibroid, number of fibroids, and total fibroid volume                                          
in relation to herpes simplex virus type 2 (HSV-2) serostatus among 365                                      
23-34 year-old African-American women with fibroids in the Study of                                  
Environment Lifestyle and Fibroids, Detroit, Michigan metropolitan area,                                        
2010-2012: odds ratios (ORs) and 95% confidence intervals (CIs) adjusted                                                   
for age, age at menarche, depot medroxyprogesterone acetate use, and parity. ..................... 61 
  
xii 
LIST OF ABBREVIATIONS 
BMI  body mass index 
BV  bacterial vaginosis 
CAWI  computer-assisted web interviewing 
CI  confidence interval 
CT  Chlamydia trachomatis 
DMPA  depot medroxyprogesterone acetate  
GED  general education development 
HFHS  Henry Ford Health System 
HSV  herpes simplex virus 
NAAT  nucleic acid amplification tests 
NIEHS  National Institute of Environmental Health Sciences 
OR  odds ratio 
PID  pelvic inflammatory disease 
PCR  polymerase chain reaction 
RTI  reproductive tract infection 
SELF  Study of Environment, Lifestyle and Fibroids 
US  United States 
UFS  Uterine Fibroid Study
 1 
CHAPTER 1: STATEMENT OF SPECIFIC AIMS 
Uterine fibroids are one of the most common gynecologic conditions affecting 
women during their reproductive years 
1
, with estimated total annual costs (direct and 
indirect) in the United States (US) of up to $34 billion 
2
. However, the cause(s) of fibroids is 
largely unknown. Many decades ago, a hypothesis was proposed that reproductive tract 
infections (RTIs) play a role in fibroid development 
3
; however, this hypothesis has never 
been adequately tested.  
More recently, two published studies 
4, 5
 have explored the relationship between RTIs 
and fibroids; both studies were based on self-reported infection histories. Results from these 
two studies were only partially consistent. The first was a clinic-based study of 318 cases and 
394 controls 
4
 which found a positive dose-response association between self-reported 
diagnosis of pelvic inflammatory disease (PID) (and the number of PID episodes) and uterine 
fibroids in premenopausal women. No association was found between self-reported history of 
genital herpes or warts and fibroids, although there was a suggestion of an increased risk of 
fibroids for women with self-reported history of Chlamydia trachomatis (CT). The second, 
the Uterine Fibroid Study (UFS) 
5
, was a cross-sectional study of 1,364 women with 
ultrasound determination of fibroid status. This study found no association of uterine fibroids 
with self-reported diagnosis of PID in either African-American or White women. However, 
there were suggestions of positive associations with self-reported history of CT infection in 
White women, and with trichomonas, syphilis, and “other infections” in African-American 
women. Self-reported history of genital herpes had suggestions of a positive association with 
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uterine fibroids in both ethnic groups 
5
. In both of these studies 
4, 5
, self-reported history of 
abnormal Pap smear was inversely associated with fibroids.  
 Building upon previous work which found suggestions of positive associations 
between a few self-reported RTIs and fibroids, our first aim was to investigate the association 
of fibroids with several self-reported RTIs in the largest sample to date. We also sought to 
explore the relationship between self-reported RTIs and the number, size, and total volume of 
fibroids which has not been previously done. Our second aim was to investigate the 
relationship between serological status of type-specific herpes simplex virus type 2 (HSV-2) 
and uterine fibroids (presence, number, size and total volume). The aforementioned studies 
of this often asymptomatic infection are limited by their use of self-reported exposure 
histories. Thus, we conducted a cross-sectional study in the ongoing Study of Environment, 
Lifestyle & Fibroids (SELF) based in the Detroit area among 1,696 African-American 
women. The primary outcome was fibroid status determined by ultrasound; the main 
exposures were self-reported histories of RTIs and seropositivity for HSV-2, measuring 
previous exposure to this pathogen. Participants with at least one fibroid ≥0.50 cm in 
diameter at enrollment ultrasound were considered to have fibroids, and all women without a 
fibroid ≥0.50 cm in diameter at enrollment ultrasound were considered not to have fibroids.  
Specifically, we aimed to: 
1. Estimate the association of fibroids (presence, number, size of the largest 
fibroid and total fibroid volume) measured by ultrasound with the following 
RTIs assessed by self-report: PID, CT, genital herpes, gonorrhea, 
trichomonas, genital warts, and bacterial vaginosis (BV)  
 3 
2. Estimate the association of fibroids with serologically-determined previous 
exposure to HSV-2  
These aims were accomplished using enrollment questionnaire data, transvaginal 
ultrasound results and serologic findings from a cohort of 1,696 African-American women 
aged 23-34 years. We used laboratory testing of the blood specimens for type-specific 
antibodies to HSV-2 using standard serologic methods to determine past exposure to 
infection. We analyzed the study data using logistic regression.  
This study was the largest to investigate the association of fibroids with several self-
reported RTIs and the first to investigate HSV-2 exposure assessed serologically. We 
hypothesized that women with a history of RTIs would have a higher prevalence of fibroids 
than women without a history of RTIs. We also explored the relationship between self-
reported RTIs and HSV-2 seropositivity and number, size, and total volume of fibroids. 
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
2.1 Uterine Fibroids (myomas or leiomyomas) 
  Uterine fibroids, benign smooth muscle cell tumors of the uterus, are one of the most 
common gynecologic conditions affecting women during their reproductive years 
1
. The 
Uterine Fibroid Study (UFS) of 1,364 randomly selected women 35 to 49 years of age 
screened by ultrasound found an estimated cumulative incidence of fibroid tumors by age 50 
of >80% for African-American women and close to 70% for White women 
6
. A pathology 
study conducted in New York showed comparable estimates; fibroids were found in 77 of the 
100 sequential uteri inspected. The uteri were removed at hysterectomy (only 33 with pre-
operative fibroid diagnosis) and were thinly sliced in 2-mm sections for analysis 
7
.   
The symptoms experienced by an estimated 20-50% of women with fibroids include 
pelvic pain and pressure, reproductive problems (infertility and adverse birth outcomes), and 
severe bleeding that can result in anemia 
1, 8-10
. These symptoms can negatively impact 
women’s quality of life including their sexual life, performance at work, relationships and 
family 
11, 12
. The primary treatment for fibroids is hysterectomy (the removal of the uterus) 
because it completely eliminates symptoms and the possibility of reemergence. Therefore, 
fibroids are the leading indication for hysterectomy in the US, accounting for 40% of 
hysterectomies or approximately 240,000 per year 
13
. However, for women who have not 
completed childbearing or who want to keep their uterus, there are other treatment options 
such as myomectomy (surgical removal of fibroids with uteri intact), uterine artery 
embolization (minimally-invasive blockage of fibroid blood supply) and focused ultrasound 
 5 
(non-invasive magnetic resonance imaging-guided sound waves that heat and destroy fibroid 
tissue) 
1, 14
. However, with these treatments there is the possibility of recurrence. There is 
also a Food and Drug Administration approved short term therapy for reducing fibroid size 
and symptoms, gonadotropin-releasing hormone agonist. However, it can only be used for 3 
to 6 months due to undesirable side effects (bone loss, hot flashes and depression), and once 
stopped, fibroids can rapidly return to their pre-treatment size 
15
.  
Ultrasound is the clinical standard for diagnosis of fibroid tumors 
16
. However, it is 
not routinely performed unless a woman is pregnant or experiencing symptoms. Thus, in 
order to estimate the true prevalence of fibroids, routine population-based ultrasound 
screening would have to be performed. The majority of previous studies have used 
hysterectomy, self-report and/or clinical diagnosis of fibroids to determine prevalence. 
However, these studies are more likely selecting women who have more severe symptoms, 
not those who may be asymptomatic. The majority of women with fibroids are 
asymptomatic. 
As a result of the management and treatment of fibroids and their associated 
complications, the total estimated costs of fibroids in the US including direct (medical and 
surgical management) and indirect (lost work time and more complicated obstetric outcomes) 
are as much as $34 billion 
2
. Thus the societal cost of fibroids in the US is more than breast 
cancer, colon cancer, or ovarian cancer and approximately one-fifth the annual cost of 
diabetes mellitus 
2
. 
Surprisingly, although fibroids have a substantial cost and public health burden, their 
pathogenesis and etiologic cause(s) are largely unknown. Fibroids are very rarely malignant, 
and it is theorized that benign and malignant tumors have a different pathogenesis 
1
. Fibroids 
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are typically classified by their size (diameter) and location- subserosal (outer uterine wall), 
submucosal (protruding into the uterine cavity) or intramural (within the uterine wall). 
Multiple tumors of various sizes (microscopic to very large) and locations are often found in 
the same uterus. Most tumors are monoclonal and thus develop independently from other 
leiomyomas in the same uterus 
17
. Although their cause is unknown, fibroids are known to be 
hormonally responsive; both estrogen and progesterone can stimulate fibroid tissue growth 
18
. 
Fibroids begin to develop after menarche 
19
 and regress after menopause 
7
. However, what 
causes the initial transformation of muscle cells into abnormal muscle cells and then what 
causes them to proliferate and grow into clinically visible tumors is not clearly understood. 
Selected risk factors that have been established for fibroids are African-American 
heritage, older age (up to the age of menopause), younger age at menarche, and nulliparity as 
well as earlier age at first birth and more years since last birth 
5, 20-22
. Other factors such as 
body mass index (BMI), smoking, hormonal contraceptive use, and alcohol have been 
inconsistently associated with fibroid risk 
5, 23, 24
. More recent studies have shown no 
association with fibroids and smoking 
24
. Previous alcohol use appears to have a positive 
relationship 
24, 25
. Oral contraceptives are prescribed to help control symptoms such as 
increased menstrual bleeding that may actually be due to fibroids 
26
. Thus, whether oral 
contraceptives are a risk factor for fibroids is difficult to tease out. Studies have shown that 
progestin-only injectables (i.e. Depo-Provera) may be protective against fibroids 
20, 27, 28
.  
Many decades ago, a hypothesis was proposed that reproductive tract infections play a role in 
fibroid development 
3
; however, this hypothesis has never been adequately tested.  
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2.2 African-American Heritage and Fibroids 
The disparate burden of fibroids among African-American women was acknowledged 
as early as the late 1800s. In Witherspoon et al. (1930), African-American women 
represented a substantial proportion of the fibroid cases (90% of 2,991 cases) at a local 
hospital although the total gynecological admissions were only slightly greater for African-
Americans compared to Whites 
3
. More recent estimates indicate that African-Americans are 
2 to 3 times more likely to have fibroids than White women 
6
. They have an earlier onset 
(~10-15 years), have more fibroids at a given age, and are more likely to have clinically 
relevant fibroids (based on size and location) than Whites 
6, 29-33
. African-Americans are also 
more likely to report severe symptoms, interference with physical activities and relationships, 
and missed work days compared to White women 
11, 34
. Additionally, a study of fibroid 
growth found that in contrast to White women, the growth rates of fibroids among African-
American women did not tend to decline as age increases 
35
. African-American women are 
also more likely to undergo hospitalization, hysterectomy and myomectomy (relative risk, 
3.5, 2.4, 6.8, respectively)  for fibroids compared to White women, consistent with more 
severe disease and an earlier age of onset 
36, 37
.  
Studies on fibroids have primarily been conducted among women who have 
undergone hysterectomy or those self-reporting symptoms, and thus select for more severe 
fibroid cases and are not representative of the general population. However, in a recent pilot 
study of asymptomatic young women 18-30 years old, 26% of the 43 African-American and 
7% of the 58 White women were ultrasound-diagnosed with fibroids 
30
. Thus, even among 
young, asymptomatic women, African-Americans appear to have a higher burden of disease. 
It is not understood why African-Americans are so disproportionately impacted by fibroids. 
There is some evidence that environmental factors such as diet 
38, 39
, stress i.e. perceived 
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racial discrimination 
40
, childhood abuse 
41
 and vitamin D insufficiency 
42
 that may differ by 
race, may be linked to fibroids. Furthermore, genetic factors could explain some of the 
burden, but this requires further investigation 
43, 44
. Witherspoon hypothesized in the 1930s 
that because both fibroids and RTIs disproportionately burden African-American women and 
certain RTIs can lead to conditions such as chronic pelvic infection that could result in 
inflammatory reactions, RTIs could play an etiological role 
3. However, since the 1930’s very 
few studies have investigated this proposed relationship.  
2.3 Infection and Fibroids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
The two recently published studies 
4, 5
 that have explored the relationship between 
RTIs and fibroids were both based on self-reported infection histories. Results from these 
two studies were only partially consistent (Table 1). The first was a clinic-based case-control 
study of fibroid risk factors in the Baltimore metropolitan area 
4
. Cases were 318 18-55 year-
old pre-menopausal women with a first diagnosis of fibroids between 1990 and 1993 
confirmed by histology or ultrasound. Controls were patients with intact uteri who had 
visited the same physicians as the cases for a routine checkup that included a pelvic exam 
without any reference to fibroids and no indication of fibroids in medical records. Cases and 
controls were frequency matched on 10 year age group, gynecologist and calendar period. 
The authors found a positive dose-response association between self-reported history of 
diagnosis of PID (and the number of PID episodes) and uterine fibroids. No association was 
found between self-reported history of genital herpes or warts and fibroids, although there 
was a suggestion of an increased risk of fibroids for women with self-reported history of CT. 
 The second was an analysis conducted using data from the UFS 
5
, which was a cross-
sectional fibroid screening study of randomly selected members of an urban health plan aged 
35-49 years. The analysis was limited to 1,016 premenopausal women with ultrasound 
 9 
determination of fibroid status and complete fibroid and questionnaire data. RTI history was 
obtained by a mail-in questionnaire and analyses were conducted separately for African-
Americans and Whites. Infections with <15 cases were excluded. This study found no 
association of uterine fibroids with self-reported diagnosis of PID in either African-American 
or White women. However, there were suggestions of positive associations with self-reported 
history of CT infection in White women, and with trichomonas, syphilis, and “other 
infections” [mainly BV] in African-American women. Self-reported history of genital herpes 
had suggestions of a positive association in both ethnic groups 
5
. In both of these studies 
4, 5
, 
self-reported history of abnormal Pap smear was inversely associated with fibroids. This 
finding was also corroborated in our recent study that showed an inverse association between 
self-reported cervical treatment and fibroids 
45
.  
Furthermore, in a small pilot study, fibroid tissue from 20 UFS participants who had 
reported a history of sexually transmitted disease(s) or multiple sex partners was searched for 
viral DNA to HSV-1 and HSV-2, cytomegalovirus, human herpes virus 6,7,8 and Epstein-
Barr virus (EBV) 
5
 using polymerase chain reaction (PCR). They did not detect any of these 
pathogens in the tumor samples but did in positive controls. However, no serological 
diagnosis was done to measure past exposure to herpes infection.  
In light of the previous studies conducted on RTIs and fibroids, the goal of this 
project was to add to the literature on self-report and more importantly to take the next step 
and use serology, an immunological measure of past infection, to better understand the 
relationship between these two conditions. We also explored the relationship between RTIs 
(self-reported and serologically measured) and fibroid characteristics (number, size and total 
volume), which has not previously been done. 
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Relatively few RTIs can be measured well serologically for epidemiologic purposes 
(mainly human immunodeficiency virus (HIV), herpes simplex virus, CT and syphilis) 
46
. 
HIV and syphilis are rarer infections, with annual reported infection rates among young 
African-American women in the US of 64 per 100,000 (25-34 year-olds) for HIV in 2010 
47
 
and 13 per 100,000 (25-29 year-olds) for syphilis in 2013 
48
 and thus are not likely to have a 
high enough seroprevalence for a well-powered analysis. Human papillomavirus (HPV) 
serology is only ~50% sensitive and the standard VLP ELISA can only measure 1 HPV type 
at a time 
49
 so it is not sufficiently feasible for measuring past exposure to HPV. In Aim 2 of 
this project we focus on serologically measured HSV-2 as the exposure. We will look at 
serology of CT in a future study.  
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Table 1. Two Recent Studies on Reproductive Tract Infections and Fibroids 
 
Self-Reported  
History of Infection 
(Ever vs. Never) 
NIEHS UFS 
OR (95% CI) 
a
 
Faerstein, et al.  
OR (95% CI) 
b
 
 African-American White  
PID 0.9 (0.5-1.9) 1.2 (0.4-3.6) 1.8 (1.0-3.1) 
   No. of Episodes ------------------- -------------------  
0 ------------------- ------------------- 1.0 
1 ------------------- ------------------- 1.4 (0.7-2.9) 
2 ------------------- ------------------- 1.6 (0.5-5.2) 
≥3 ------------------- ------------------- 3.7 (0.9-15.9) 
Genital herpes 1.6 (0.7-3.6) 1.4 (0.7-2.8) 0.8 (0.3-2.2) 
Genital warts 1.1 (0.5-2.2) 1.0 (0.5-2.0) 1.0 (0.4-2.5) 
Chlamydia 1.1 (0.6-2.4) 1.7 (0.6-4.9) 3.2 (0.8-13.7) 
Gonorrhea 1.3 (0.7-2.2) NR ---------------------- 
Trichomonas 3.1 (0.9-10.7) NR ---------------------- 
Syphilis 2.2 (0.6-7.8) NR ---------------------- 
Other (mainly BV) 2.1 (0.8–5.6) 1.1 (0.4–3.2) ---------------------- 
Abnormal Pap Smear 0.6 (0.4-1.0) 0.8 (0.4-1.4) 0.5 (0.3-1.0) 
 
BV, bacterial vaginosis; CI, confidence interval; NIEHS, National Institute of Environmental Health 
Sciences; NR, not reported (<15 cases); OR, odds ratio; PID, pelvic inflammatory disease; UFS, 
Uterine Fibroid Study
  
 a 
Adjusted for age, age of menarche, full-term pregnancies after age 24, and body mass index;   
b 
Adjusted for clinic, ethnicity       
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2.4 Reproductive Tract Infections 
Reproductive tract infections (RTIs) are a substantial public health problem in the US 
with an estimated 110 million prevalent infections and 20 million incident infections in 2008 
50
. RTIs also cost the US health care system close to $16 billion in health care costs every 
year. Youth 15-24 years of age account for half of all new RTIs, while representing only 25% 
of the sexually active population 
50
. In addition, in women, these infections can result in 
reproductive complications; it is estimated that undiagnosed RTIs cause 24,000 women to 
become infertile each year 
51
. Some of the risk factors for RTIs include young age, African-
American race/ethnicity, lower socio-economic status (education, income, etc.), substance 
abuse, heavy alcohol use, single marital status, use of oral contraceptives and higher number 
of sexual partners (as well as other sexual behavior characteristics) 
52-56
. A brief description 
of the self-reported RTIs of interest (Aim 1) follows. The special focus of this project was on 
the relationship between fibroids and serologically-determined HSV-2 (Aim 2); thus, this 
infection will be described in more detail.  
2.4.1 Self-reported RTIs of Interest 
Pelvic inflammatory disease is inflammation of the upper female reproductive tract 
caused by infection. Based on a nationally representative sample from 2006-2010, 5% of US 
women have reported being treated for PID in their lifetime 
57
. It is a major concern because 
PID can result in infertility, ectopic pregnancy and chronic pelvic pain 
58
. One in 8 women 
with a history of PID experience difficulties getting pregnant 
59
. The majority of cases are 
due to sexually transmitted infections such as CT and gonorrhea as well as BV and 
Mycoplasma genitalium 
58
. The clinical diagnosis of PID is based on the finding of pelvic 
organ tenderness along with signs of lower genital tract inflammation. Furthermore, women 
with potential PID should be tested for CT and gonorrhea. The treatment of PID involves the 
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use of antimicrobials to eliminate likely pathogens such as CT and gonorrhea, regardless of 
the results of testing 
58
. Repeated episodes of pelvic inflammatory disease appreciably 
worsen reproductive outcomes 
60, 61
. Thus, it is very important to continue to work to control 
CT and gonorrhea infection in order to prevent the development of PID.   
CT is the most commonly reported bacterial RTI in the US with about 3 million new 
infections each year 
50
. However, a large proportion of cases are asymptomatic and 
unrecognized. Thus, only a minority of cases are clinically reported. If symptoms do arise, 
they are commonly abnormal vaginal discharge, vaginal bleeding (including bleeding after 
intercourse), and painful urination. Young adults (<25 years of age) and African-Americans 
are disproportionately affected by CT infection (incidence among African-American women 
is estimated to be 7 times higher than among White women) 
50
.  
CT can be treated and cured with antibiotics. However, untreated CT infections of the 
upper genital tract can result in long-term sequelae such as PID (~10-15% of CT cases), 
salpingitis, endometritis, and perihepatitis 
62
. Salpingitis can lead to tubal scarring and 
reproductive complications such as tubal-factor infertility and ectopic pregnancy. Symptoms 
of these sequelae may include abnormal uterine bleeding, pelvic discomfort, or chronic 
abdominal pain 
62
 although these conditions are commonly “silent” with no or minimal signs 
or symptoms. In pregnant women, CT is also associated with preterm delivery and can be 
spread to newborns resulting in eye infection or pneumonia 
63
. CT typically infects columnar 
or transitional epithelium of the urethra, cervix-extending to the endometrium, fallopian 
tubes, and peritoneum (membrane lining the abdominal cavity)- and rectum 
64
.  
For years culture was the principal diagnostic method for CT. Many non-culture tests 
are now available, with the most sensitive being nucleic acid amplification tests (NAATs) 
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that are also able to test urine and thus do not require collection of specimens from the cervix 
or urethra 
64
. Serologic testing as a means of diagnosis may be helpful for more complicated 
CT infections, such as lymphogranuloma venereum or neonatal pneumonia, and possibly as a 
screening test for tubal factor infertility; however, it is not often clinically utilized 
62
. 
Gonorrhea is a common bacterial RTI with over 800,000 new infections annually; 
however, less than half are detected and reported 
65
. Symptoms may include a painful or 
burning sensation when urinating, increased vaginal discharge, or vaginal bleeding between 
periods. Most cases are asymptomatic. Among women, the most common site of infection is 
the endocervical canal 
66
. Similar to CT in women, gonorrhea can lead to salpingitis or PID 
and ectopic pregnancy 
66
. In addition, if left untreated, it can spread to the blood and cause 
disseminated gonococcal infection, a systemic complication which can be life threatening 
65
. 
Gonorrhea is typically diagnosed with a urine test (NAAT), by culture or nucleic acid 
hybridization tests, and can be treated with antibiotics; however, drug-resistant strains are 
becoming more prevalent 
67
.    
 Trichomoniasis is caused by infection with the protozoan parasite, Trichomonas 
vaginalis, and is the most common curable (non-viral) RTI in the US, with close to 4 million 
people infected 
68
. It is more prevalent among women than men; and, unlike other RTIs, it is 
associated with older age among women 
68, 69
. From 2001-2004, the prevalence of 
trichomoniasis in the US, among women 14-49 years of age, was 13% among African-
Americans and only 3% overall 
69
. It is also highly associated with other RTIs and is an 
important risk-factor for HIV 
70
. Many infected women are asymptomatic; however, up to 
50% may have symptoms ranging from mild irritation to vaginitis 
70
. Some symptoms 
include itching, foul odor, yellow-green discharge, and bleeding after sex. Trichomoniasis 
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can be cured with a single dose of prescription metronidazole or tinidazole. However, after 
treatment, 1 in 5 people will be re-infected 
68
. It is usually diagnosed clinically by 
microscopic examination of urine/discharge or by culture, which is the gold standard 
70
. 
Furthermore, infection with trichomoniasis has been found to be associated with preterm 
delivery and low birth weight as well as PID 
71, 72
.  
Genital warts are small external bumps or groups of bumps predominately (90%) 
caused by HPV type 6 and 11 
73
. They are usually asymptomatic, but at times may be painful 
or itchy. The four morphologic types of genital warts include: condylomata acuminata 
(cauliflower shaped), papular (flesh-colored round papules), keratotic (thick, crusty layer) 
and slightly raised, flat-topped papules 
74
. They are usually located on the introitis, vulva, 
perineum, and perianal area in women although they can also be found on the cervix, vaginal 
wall, pubic area, upper thighs, and crural fold 
74
. They are typically diagnosed clinically by 
visual inspection or biopsy and, if left untreated, may resolve naturally, get larger, or remain 
the same. Treatment (patient-applied or provider-administered) varies depending on the size, 
location, symptoms, and patient preference. Treatment only targets the warts, not the virus 
itself, although it may reduce the amount of infectious virus present and thus, the probability 
of transmission 
74
. 
Bacterial vaginosis is a condition in women where the normal bacteria in vaginal 
fluid is replaced by an overgrowth of certain bacteria 
75
. It is the most common cause of 
vaginal symptoms among women of childbearing age. It does not tend to cause inflammation 
or tissue damage and thus is more so a disturbance of the vaginal microflora 
76
. Most women 
do not have symptoms; however, it is sometimes accompanied by white/gray discharge, fishy 
odor, pain, itching, or burning. The cause and route of transmission of BV is not clearly 
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understood. Thus, it may not be solely sexually transmitted, so women who are not sexually 
active are at risk. However, exposure to new or multiple sex partners has been shown to 
increase the incidence of BV, and younger sexual debut has been found to be associated with 
BV 
76
. Intrauterine device use and douching have also been found to be risk factors 
76
.  
Furthermore, BV has been shown to be associated with PID as well as low birth weight and 
premature delivery among pregnant women 
76
. BV is diagnosed by microscopic examination 
and the presence of other signs (white discharge, vaginal fluid pH > 4.5 and fishy odor) and 
is usually treated with either metronidazole or clindamycin 
76
. 
2.4.2 Herpes Simplex Virus-2 (HSV-2) 
 Herpes simplex virus-2 is the main cause of genital and neonatal herpes and one of 
the most common RTIs worldwide. In the US, 1 out of 6 people between the ages of 14 and 
49 have genital herpes antibodies or clinical disease and women are more susceptible to 
infection than men 
55, 77
. In addition, African-Americans are 3-4 times as likely to have HSV-
2 as Whites 
55
. According to National Health and Nutrition Examination Survey (NHANES) 
data from 2007-2010, the HSV-2 seroprevalence for 14-49 year-olds overall, among women, 
and among African-American women was 16%, 20%, and 50%, respectively 
55
. People living 
with HSV-2 are also 2 times as likely to acquire HIV infection 
78
.  Other main risk factors for 
HSV-2 include: higher numbers of sexual partners, heavy alcohol use, low socioeconomic 
status, being unpartnered vs. married/cohabiting and lack of consistent condom use 
55, 79-83
. 
Also, Depo-Provera use may increase risk of HSV-2 seroconversion 
84, 85
. Early age at 
menarche has been found to be associated with HSV-2 
86
 and has been identified as a 
predictor of early sexual behavior, a factor highly associated with HSV-2 
87, 88
. 
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HSV-2 can lead to painful chronic infection, spontaneous abortion, and fatal infection 
in newborns (neonatal herpes). HSV-2 accounts for 70% of neonatal HSV cases. Neonatal 
HSV-2 is transmitted transplacentally (or congenitally) in about 5 to 10% of cases but the 
majority of cases occur as a result of perinatal contact with the maternal genital tract when a 
woman has a newly acquired primary infection (seronegative for HSV-2) close to delivery 
89
. 
The symptoms of HSV-2 are primarily lesions (blisters that later ulcerate) at the site 
of infection which can be very mild to painful. Other symptoms of primary infection may 
include fever, painful urination, swollen or tender lymph nodes in the groin area, and a 
general sick feeling (malaise). However, some people may not have any symptoms. 
Transmission usually occurs from sexual contact with an infected but asymptomatic 
individual (in about 70% of cases) because HSV-2 can be excreted or shed in the absence of 
symptoms 
90
.   
 There is no treatment that can cure HSV-2; thus it is a lifelong companion. In fact, 
HSV-2 has a biologic property of staying latent in the dorsal nerve ganglia and reactivating, 
which can cause recurrent lesions at or near the initial site of infection or asymptomatic viral 
shedding. Generally, about 90% of symptomatic HSV-2 infected individuals will have one or 
more recurrences a year 
91
. Symptoms of recurrent outbreaks are typically shorter in duration 
and less severe (shorter period of shedding and fewer lesions) than the first outbreak of HSV-
2 
77
. HSV-2 is clinically diagnosed with culture or PCR of tissue during active infection 
when a blister is present. However, most HSV-2 infections are asymptomatic or 
unrecognized (over 85% of seropositive African-American women reported no history of 
diagnosis) 
55
; thus, seropositivity to HSV-2 is the best estimate of cumulative past exposure 
55, 79
. 
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HSV-1 causes approximately 30% of genital herpes infections, but more recently 
proportions have been found of over 50% especially among college students 
92
. Initial 
episodes of HSV-1 are clinically indistinguishable from HSV-2; however, it is characterized 
by fewer recurrences of lesions and less viral shedding than HSV-2 infection 
93
. HSV-1 and 
HSV-2 have an intricate relationship that is still being explored.  
2.5 Biological Mechanisms of Tumorigenesis Following Infection 
Infectious agents have been linked to several neoplasms, with approximately 18% of 
cancers estimated to be due to infection (i.e. HPV, hepatitis B and C viruses, and 
Helicobacter pylori) 
94
. Leiomyomas have also been linked to infection; one study found an 
increased risk of EBV-associated leiomyosarcoma and leiomyoma among children with HIV 
95
. Large quantities of EBV were detected in the tumor cells. These tumors were not in the 
uterus, but the findings reveal that smooth muscle cells may have the ability to undergo 
virally-initiated tumorigenesis. There has also been an association reported between Chagas 
disease, a parasitic infection endemic in South America, and fibroids 
96
. This parasite can 
also infect uterine smooth muscle cells. Thus, a biological mechanism for infection-related 
oncogenesis may also apply to the pathogenesis of fibroids 
97
. 
HSV-2 has been isolated from the upper genital tract including the cervix 
98
 and 
endometrium 
72, 99
 and has also been found to infect the placenta 
89, 100
. HSV-2 infection also 
induces an inflammatory response and can cause cervicitis which is highly associated with 
ulceration and necrosis 
93
. Inflammation is an acute or chronic non-specific immune response 
the body uses to respond to infection and can be both beneficial and harmful 
101
. For 
example, chronic inflammation is one of the primary mechanisms through which infections 
induce neoplastic lesions 
94
 usually through an increase in cell proliferation. Some infectious 
agents cause necrosis (premature cell death) which leads to a subsequent increase in cell 
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proliferation and tissue regeneration, and others may cause a decrease in apoptosis 
(programmed cell death) which increases cell proliferation 
97
.  
One theorized mechanism for fibroid development is seen in Figure 1. Briefly, 
infection can stimulate an inflammatory immune response which can facilitate the initiation 
of tissue damage resulting in tissue repair/regeneration (increased extracellular matrix, cell 
proliferation, decreased apoptosis, etc.), leading to the formation and growth of uterine 
fibroids 
102, 103
. The chronic inflammatory state can increase local estrogen production, which 
increases proliferation 
104
. This mechanism is consistent with other theories of fibroid 
pathogenesis. Cramer et al. proposed that myometrial hyperplasia, areas of increased 
cellularity and nucleus/cell ratio compared to normal myometrium in the same uterus, is one 
of the pathogenic pathways of fibroid development 
105
. Myometrial hyperplasia appears to 
originate as early as adolescence at the junctional zone of the uterus between the 
endometrium and myometrium 
105
 and can extend into the myometrium. Thus, paracrine 
signaling from infected endometrial cells to myometrial cells may also play a role. In 
addition, Leppert et al. proposed that fibroids develop as a result of an abnormal response to 
tissue repair (a lack of apoptosis which leads to chronically active cell proliferation and 
excess extracellular matrix) similar to abnormal wound healing 
102
, which could be initiated 
by infection.  
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Figure 1. Theorized Mechanism for Infection and Fibroids  
     (Adapted from Wegienka, 2012 
103
) 
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CHAPTER 3: RESEARCH DESIGN AND METHODS 
3.1 Overview 
For this project, we used transvaginal ultrasound results, self-reported questionnaire 
data and blood samples collected from participants in the ongoing NIEHS SELF study based 
in the Detroit area. We used a cross-sectional study design with history of RTIs measured by 
self-report (Aim 1) and serology (Aim 2) as the exposures of interest. Fibroid status 
measured by enrollment ultrasound was the primary outcome. Fibroid characteristics i.e., size 
of the largest fibroid, the number of fibroids and the total fibroid volume, were also 
examined as secondary outcomes. 
3.2 Study Participants and Data Collection  
SELF is a prospective cohort study of fibroid development. From November 2010 to 
December 2012, the study recruited a volunteer sample of 1,696 African-American women 
ages 23–34 without a prior diagnosis of fibroids. Recruitment was designed to saturate the 
recruitment area (Detroit, Michigan and the surrounding area) with information about the 
study. Materials included a website (detroitself.org); flyers; brochures at health care clinics; 
local radio, television, newspaper, and magazine advertisements; information booths at 
community events, and letters to women who had been seen in the past year by a doctor at 
the Henry Ford Health System (HFHS). HFHS is a large medical provider in the Detroit area 
and a collaborating institution. The letters were sent to women listed as 23–34 years of age, 
with stratification by age to help achieve equal recruitment by age. This age group was 
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chosen on the basis of ultrasound screening data 
29
, to capture women early enough to have a 
sizeable proportion without fibroids.  
Women who were interested in learning more about the study contacted the study by 
phone or e-mail. Prospective participants were screened for eligibility by phone. Women 
were not eligible for SELF if they had previously been diagnosed with uterine fibroids; had a 
hysterectomy; had ever taken medication to treat lupus, Grave's disease, Sjogren's 
scleroderma, or multiple sclerosis; or ever had any type of cancer treated with radiation or 
chemotherapy. Eligible prospective participants received detailed information about the study 
during an orientation session. Those who chose to enroll after the orientation gave informed 
consent and completed self-administered questionnaires and a telephone interview, and had a 
standardized research ultrasound examination to screen for the presence of fibroids. Some 
women had fibroids at enrollment of which they were unaware.  
Women pregnant at recruitment were delayed enrollment until 4 months after 
delivery so that pregnancy did not interfere with ultrasound assessment of fibroids. SELF 
participants will be followed for at least 5 years after enrollment, with subsequent ultrasound 
examinations every 20 months. Women who screened negative at enrollment will be 
followed for fibroid development; women who screened positive at enrollment and those 
who develop incident fibroids will be followed for development of additional fibroids and 
fibroid growth. The study was approved by the institutional review boards of the NIEHS and 
HFHS. 
3.3 Outcome Assessment 
Ultrasound is the standard procedure for the detection and diagnosis of fibroids 
16
 and 
it is as accurate as magnetic resonance imaging for women with no more than four fibroids 
16
. If there were problems with transvaginal visualization, an abdominal scan was also 
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completed. Focal fibroids of 0.50 cm diameter or greater were recorded. A data-collection 
form designed for the study was completed by the sonographer for each examination, which 
included documentation of the number, size and location of the fibroids. The diameters of the 
6 largest fibroids were measured in cm longitudinally, anterior-posteriorly and transversely 
three separate times (thus, a participant with at least 6 fibroids ≥0.50 cm will have 18 fibroid 
measurements). Questionable fibroids were those where at least 1 diameter could not be 
measured. Sonographers recorded the number of fibroids visualized (up to 10) as well as the 
number of questionable fibroids visualized (up to 10). If more than 10 fibroids were seen, the 
number 10 was recorded on the form. All ultrasounds were conducted by sonographers at one 
of three HFHS clinics. To ensure the quality of these ultrasound data, study sonographers 
were required to have at least 3 years of experience in gynecologic ultrasound, receive formal 
training for the study, and be individually monitored by the head sonographer during their 
first 10 study examinations. A video clip of the uterus and still images of all measurements 
were archived for each ultrasound examination, and a random selection of 8% of each 
sonographer's ultrasound examinations, stratified to oversample participants with fibroids, 
was checked by comparing the data collected with the archived images. 
3.3.1 Outcome Definitions 
 
The primary outcome of this study was fibroid presence (yes/no) at the transvaginal 
ultrasound examination completed at enrollment. Thus, participants who had at least one 
fibroid or questionable fibroid ≥0.5 cm in diameter at enrollment ultrasound (22%; n=377) 
were considered to have fibroids, and all the women who did have a fibroid or questionable 
fibroid ≥0.5 cm in diameter at enrollment ultrasound (n=1,319) were considered not to have 
fibroids. The secondary outcomes were size of the largest fibroid, total fibroid volume and 
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the number of fibroids at enrollment ultrasound. The size of the largest fibroid was 
determined by averaging the maximum dimension of each set of fibroid measurements for 
each participant. Total fibroid volume (cm
3
) was measured by computing the volumes of 
each of the 3 sets of measurements (longitudinal diameter [L], anterior-posterior [A] 
diameter and transverse [T] diameter) using the ellipsoid formula (L x A x T x 0.5233), 
taking the average volume of the 3 and then summing the average volumes from each of the 
fibroids.  
3.4 Exposure Assessment 
For specific information on exposure assessment for each Aim, please refer to Chapters 4 and 
5 below.  
3.5 Covariates 
Extensive data on demographic characteristics, medical history, medication use and 
personal history was collected at enrollment.  Variables of interest assessed at the enrollment 
telephone interview include: age at menarche, parity, type of contraceptive used and cervical 
treatment history. Weight and height used to calculate body mass index (weight [kg]/height 
[m]
2
) were measured at the enrollment clinic visit. The web-based questionnaire at 
enrollment included questions on education, employment, income, alcohol and sexual 
behavior variables such as age at first intercourse, and number of sexual partners before age 
20. 
3.6 Statistical Analyses 
3.6.1 Data Preparation 
 
In order to prepare the data for analysis, each variable of interest was renamed in a 
standard manner to enable easy recognition. In addition, each variable was explored for 
impossible or unusual values. We also performed cross-tabulations between variables to 
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check for consistency and logic. For example, did participants who reported never being 
sexually active also report “No” for ever being diagnosed with an RTI? Because the majority 
of questions were asked via telephone interview or web-based interview where participants 
had to respond to a question before proceeding, there was very minimal missing data. 
However, participants were able to respond “prefer not to answer.” Any “prefer not to 
answer” response was coded as missing and subjects with missing values were excluded 
from relevant statistical analyses. In addition, different coding schemes/methods of 
collapsing multi-level variables were evaluated based on the distribution of the data and 
comparability with the literature.  
3.6.2 Descriptive Analyses 
 Standard descriptive statistics were reviewed for all variables of interest (exposures, 
outcomes and covariates). For categorical variables, proportions at each level were described. 
For continuous variables (age, age at menarche, BMI, etc.) the shape of the distribution was 
described graphically with means (standard deviations), medians (interquartile ranges), 
ranges and spread (skewness and kurtosis) to confirm that values were plausible. All 
continuous covariates were assessed for linearity of their association with the outcome. The 
assumption of linearity in the logit was evaluated by plotting logits and examining the 
incremental OR of the variable-outcome relationship. If the assumptions were violated, other 
coding schemes such as common referent indicator variable coding, category scores (using 
the median value for each category), and power transformations (quadratic, cubic, etc.) were 
explored. BMI is a continuous variable but was categorized by common cut-points for 
comparison with the literature.  
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 Correlations between sociodemographic covariates, education and income, were 
assessed by evaluating the bivariable distributions and strength of age-adjusted ORs (95% 
CIs). Because these socioeconomic variables were, we elected to use only education, which 
had the stronger association with the outcome. In addition, although we did not have reason 
to believe that sexual behavior is related to fibroids except through the RTI pathway, we 
evaluated the relationship between each RTI and the sexual behavior variables (number of 
sexual partners, age at first intercourse, etc.) for comparison with the literature. Age of 
menarche has not been found to be directly associated with RTIs; however, it has been 
identified as a predictor of sexual behavior which is highly associated with RTIs 
87, 88
. 
 Potential confounders and variables of interest were determined based on a review of 
the literature, and a directed acyclic graph 
106
 was used to provide a conceptual framework 
(see Appendix Figure 1). Potential confounders included: age in years (continuous), age at 
menarche (7 to 10, 11 to 19 years), alcohol (low, moderate, heavy), and use of Depo-Provera 
(ever, never). The alcohol variable reflected the drinking level each woman reported for the 
age(s) when she was drinking the most. Low drinkers were those who never had 10 or more 
drinks in any one year. Heavy drinkers were those who usually drank 6 or more drinks on 
days when they drank or drank 4+ drinks per sitting at least 2 to 3 times a month. Moderate 
drinkers were all others. Variables of interest based on the literature included education (high 
school/general education development or less, some college/associates/technical, 
bachelors/masters/doctorate) and BMI (15-24, 25-29, 30-34, ≥35) in kg/m2; parity 
(nulliparous, parous) was included to increase precision because of the consistent association 
between parity and fibroids in the literature.  
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Please see chapters 4 and 5 below for more specific information on statistical 
analyses. 
3.6.12 Power Calculations 
Because we knew the number of total fibroid cases (n=377) and the number of non-
cases (n=1,319), we calculated power based on an unmatched case-control design using 
Episheet (2012) 
107
. The table below shows the ORs detectable with 80% power, two-sided 
alpha=0.05, a 3 to 1 ratio of controls to cases, and an exposure prevalence in the source 
population ranging from 5% to 50%.  
Table 2. Detectable Odds Ratio with 80% Power 
 
Power Exposure Prevalence of Non-Diseased 
 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
80% 1.79 1.57 1.47 1.42 1.39 1.37 1.36 1.35 1.35 1.35 
 
In SELF, ever being diagnosed with chlamydia and BV was reported by 37%, 
trichomonas by 32%, gonorrhea by 19%, genital herpes by 8, genital warts by 7% and PID 
by 10%. Thus, we had 80% power to detect odds ratios of 1.4 to 1.8 with the self-reported 
data.  The estimated seroprevalence of HSV-2 among African-American females is 50% 
79
. 
Thus, for Aim 2 with an estimated seroprevalence of > 20% for HSV-2 in the source 
population, we had 80% power to detect an OR of 1.4.  
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CHAPTER 4: SELF-REPORTED REPRODUCTIVE TRACT INFECTIONS AND 
ULTRASOUND DIAGNOSED UTERINE FIBROIDS IN AFRICAN-AMERICAN 
WOMEN
1
 
4.1 Introduction 
Uterine fibroids, benign smooth-muscle-cell tumors of the uterus, are one of the most 
common gynecologic conditions affecting women during their reproductive years 
1
. By age 
50, the estimated risk of developing fibroids is >80% for African-American women and close 
to 70% for White women 
6
. The majority of women with fibroids are asymptomatic; 
however, an estimated 20-50% of women experience symptoms, i.e., pelvic pain and 
pressure, severe bleeding and reproductive problems 
1, 8-10
. The primary treatment for fibroids 
is hysterectomy and they are the leading indication in the US, accounting for 40% of all 
procedures. The total estimated costs of fibroids in the US are as much as $34 billion 
annually 
2
.  
Although fibroids are responsible for substantial morbidity and public health burden, 
their pathogenesis and etiology are largely unknown. Fibroids are hormonally responsive 
18
; 
they develop after menarche 
19
 and tend to regress after menopause 
7
. However, what causes 
the initial transformation of muscle cells into abnormal muscle cells and then their 
proliferation and growth into clinically visible tumors is not understood. 
Risk factors that have been established for fibroids are African-American heritage 
(African-Americans are 2 to 3 times as likely to have clinically recognized fibroids as White 
                                                 
1
This whole chapter was taken from: Moore KR, Cole SR, Dittmer DP, et al. Self-Reported Reproductive Tract 
Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. Journal of Women's 
Health 2015; 24(6):489-95. 
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women 
6
), older age (up to the age of menopause), younger age at menarche, and nulliparity 
5, 20-22
. Other factors such as BMI, smoking, and hormonal contraceptive use have been 
inconsistently associated with fibroid risk 
5, 23, 24
. More recent studies have shown no 
association with fibroids and smoking 
24
. Two studies have reported that progestin-only 
injectables (i.e. Depo-Provera) may be protective 
20, 27
. Alcohol use may be a risk factor, but 
the number of studies is small 
24, 25
. 
In the 1930s, Witherspoon 
3
 hypothesized that RTIs play an etiological role in fibroid 
development. Both RTIs and fibroids disproportionately burden African-American women 
and certain RTIs can lead to conditions, i.e., chronic pelvic infection that could result in 
inflammatory reactions. Rates of reportable RTIs, i.e., CT and gonorrhea, are 6 and 14 times 
as high among African-American women compared to White women, respectively 
108
. In 
addition, rates of CT and gonorrhea are highest among younger women ages 15-24 years 
which is, in most cases, the period before the diagnosis of fibroids 
50
. This hypothesis is 
consistent with another theorized mechanism of fibroid pathogenesis involving tissue damage 
and aberrant tissue repair/regeneration (increased extracellular matrix, cell proliferation, and 
decreased apoptosis), leading to the formation and growth of uterine fibroids 
102, 103
.   
Yet, very few studies have investigated the effect of RTIs on fibroid development. 
The two recently published studies have only partially consistent results 
4, 5
. The first was a 
clinic-based case-control study of fibroid risk factors in the Baltimore metropolitan area with 
fibroids confirmed by histology or ultrasound 
4
. A positive dose-response association was 
observed between the number of self-reported PID episodes and uterine fibroids. No 
association was found between self-reported history of genital herpes or warts and fibroids, 
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although there was a suggestion of an increased odds of fibroids for women with self-
reported history of CT 
4
.   
The UFS 
5
 was a cross-sectional study of randomly selected members of an urban 
health plan screened for fibroids with ultrasound. No association of fibroids was found with 
self-reported diagnosis of PID. However, there were suggestions of positive associations with 
self-reported history of CT in White women, and with trichomonas, syphilis, and “other 
infections” [mainly BV] in African-American women. Self-reported history of genital herpes 
had non-significant elevated ORs in both ethnic groups 
5
. In both studies 
4, 5
 self-reported 
history of abnormal Pap smear was inversely associated with fibroids. This finding was also 
corroborated in our recent study that showed an inverse association between self-reported 
cervical treatment and fibroids 
109
.  
A small study of 20 UFS participants examined fibroid tissue for evidence of HSV-1 
and HSV-2, cytomegalovirus, human herpes virus 6,7,8, EBV and CT 
5
 using PCR and 
histology. They did not detect any evidence of these pathogens in the tumor samples.  
The goal of this study was to further investigate the relationship between self-reported 
RTIs and fibroids in a large study of African-American women with ultrasound screening for 
fibroids. We also explored the relationship between self-reported RTIs and number, size and 
total volume of fibroids which has not previously been done.  
4.2 Methods 
We used transvaginal ultrasound results and self-reported questionnaire data from 
participants in the ongoing NIEHS SELF study based in the Detroit area. We used cross-
sectional enrollment data with history of RTIs measured by self-report as the exposures of 
interest. Fibroid status measured by ultrasound at enrollment was the outcome. Secondary 
outcomes were size of the largest fibroid, number of fibroids, and total fibroid volume. 
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4.2.3 Study Participants and Data Collection  
SELF is a prospective cohort study of fibroid development. Enrollment and data 
collection have been described previously 
109
. In brief, from November 2010 to December 
2012, the study enrolled a volunteer sample of 1,696 African-American women ages 23–34 
without a prior diagnosis of fibroids in the Detroit, Michigan area. Women were not eligible 
for SELF if they had previously been diagnosed with uterine fibroids; had a hysterectomy; 
had ever taken medication to treat lupus, Grave's disease, Sjogren's scleroderma, or multiple 
sclerosis; or ever had any type of cancer treated with radiation or chemotherapy.  
During 2010 to 2012, recruitment materials, primarily composed of targeted letters, 
media announcements and flyers, were distributed throughout the Detroit area with the aim 
of informing the target population about the study. Interested volunteers called the study 
number and began the enrollment process including an orientation that thoroughly described 
study activities. Those that completed all enrollment questionnaires and a clinic visit with 
ultrasound were enrolled. Participants gave written informed consent. The study was 
approved by the institutional review boards of NIEHS and HFHS, a large medical provider in 
the Detroit area and a collaborating institution. 
4.2.4 Fibroid Assessment 
Transvaginal ultrasound is the standard procedure for the detection and diagnosis of 
fibroids 
16
. It is as accurate as magnetic resonance imaging for women with no more than 
four fibroids 
16
. Fibroids were assessed by study sonographers as described previously 
110
 at 
one of three HFHS clinics. Focal fibroids of 0.5 cm diameter or greater were measured in 
triplicate. For each measurement, the 3 perpendicular diameters (longitudinal [L], anterior-
posterior [A] and transverse [T]) were recorded.   
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4.2.5 Outcome Definitions 
The primary outcome of this study was fibroid presence (yes/no) at the transvaginal 
ultrasound examination completed at enrollment. Questionable fibroids were those where at 
least 1 diameter could not be measured. Participants who had at least one fibroid or 
questionable fibroid ≥0.5 cm at enrollment ultrasound (22%; n=377) were considered to have 
fibroids, and all women who did not have a fibroid or questionable fibroid ≥0.5 cm in 
diameter at enrollment ultrasound (n=1,319) were considered to not have fibroids. The 
secondary outcomes were size of the largest fibroid, number of fibroids and total fibroid 
volume. The size of the largest fibroid was determined by averaging the maximum diameter 
(L, A or T) of each of the triplicate fibroid measurements. Fibroid volume (cm
3
) was 
measured by computing the volumes of each of the triplicate fibroid measurements using the 
ellipsoid formula (L x A x T x 0.5233), and averaging across the three volumes. Total fibroid 
volume (cm
3
) was calculated by adding the average volumes from each of a woman’s 
fibroids. Total fibroid volume was not computed for women with only questionable fibroids 
(n=6) because at least 1 diameter was not measured.  
4.2.6 Reproductive Tract Infection Assessment 
At enrollment, SELF participants responded to questions regarding their history of 
RTIs via a self-administered computer-assisted web interviewing (CAWI) questionnaire. 
Each question on the CAWI required an answer before the next question was presented. If no 
answer was recorded, the same question was presented again, but an additional response 
category was offered: “prefer not to answer.”  
The questions of interest used for this study were: 1. Has a doctor or other health 
professional ever told you that you had...?  2. How old were you when you were first 
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diagnosed with...?  3. In total, how many times have you been diagnosed with...? These 
questions were asked for PID, CT, BV, gonorrhea, trichomonas, genital herpes and genital 
warts. 
For each RTI, those exposed were the women who reported “Yes” to ever being 
diagnosed with that particular RTI. The unexposed were those who reported “No” to ever 
being diagnosed with that particular RTI. We also created a variable, “any RTI”, representing 
whether the participant had been diagnosed with any of the aforementioned RTIs. The 
exposed group included those who self-reported at least one RTI diagnosis and the 
unexposed group comprised those who did not self-report any RTI diagnosis. Two 
participants were not included because they responded “prefer not to answer” for at least 1 
RTI and reported “No” for other RTIs; thus, we could not determine their “any RTI” status. 
4.2.7 Statistical Analyses 
Because the majority of questions were asked via telephone or web-based interview 
where participants had to respond to a question before proceeding, there was minimal 
missing data. Any “prefer not to answer” response (0.06% to 0.12%) was coded as missing, 
and complete case analysis was performed. Variables were categorized based on the 
distribution of the data and comparability with the literature. All analyses were completed on 
women who reported ever being sexually active and who did not self-report a diagnosis of 
HIV or use of HIV medications. Standard descriptive statistics were performed for all 
variables of interest. For categorical variables, proportions at each level were described. For 
continuous variables, medians (interquartile ranges) were computed. Although sexual 
behavior variables are not confounders, we described the relationship between each RTI and 
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number of sexual partners and age at first intercourse for comparison with the literature. All 
analyses were conducted with SAS 9.3.  
4.2.7.1 Primary Analyses: Association between RTIs and Fibroid Presence 
 Logistic regression models were used to compute ORs and 95% CIs to evaluate the 
associations between the self-reported RTI related variables (PID, CT gonorrhea, 
trichomonas, BV, genital herpes and genital warts) and fibroid presence. Because fibroids are 
common, the relative odds will overestimate the relative risk, but it provides a valid method 
of testing for statistically significant differences between those with and without a self-
reported RTI diagnosis. Potential confounders and variables of interest were determined 
based on a review of the literature and a directed acyclic graph, and were included in the full 
model: age in years (continuous), age at menarche (7 to 10, 11 to 19 years), parity 
(nulliparous, parous), education (high school/general education development (GED) or less, 
some college/associates/technical, bachelors/masters/PhD), BMI (15-24, 25-29, 30-34, ≥35) 
in kg/m
2
, alcohol (low, moderate, heavy), and use of Depo-Provera (ever, never). The alcohol 
variable reflected the drinking level each woman reported for the age(s) when she was 
drinking the most. Low drinkers were those who never had 10 or more drinks in a year. 
Heavy drinkers were those who usually drank 6 or more drinks on days when they drank or 
drank 4+ drinks per sitting at least 2 to 3 times a month. Moderate drinkers were all others.  
We evaluated the association of “any RTI”, and each self-reported RTI with fibroids 
in both age- and multivariable-adjusted models. To control for confounding of an RTI-fibroid 
association by another RTI, all RTIs were included in the multivariable-adjusted model 
together (with the exception of PID which was modeled separately because it can share 
causal pathways with other RTIs (e.g., CT can cause PID, so only the proximate factor, PID, 
 35 
would be included in a model investigating effects of PID)). Spearman partial correlations 
(adjusted for age) among the other RTIs were assessed to assure they were not highly 
correlated (Suppl. Table 1). 
4.2.7.2 Secondary Analyses 
As a secondary analysis we examined the association between RTIs and 3 outcomes: 
size of the largest fibroid, number of fibroids and total fibroid volume. Medians rounded to 
the nearest whole number were used to determine category cutpoints for size of the largest 
fibroid and total fibroid volume (2 cm and 2 cm
3
, respectively). To estimate the ORs and 
95% CIs for the association of “any RTI” and each RTI and fibroids, we used multinomial 
logistic regression with the same potential confounders as in the primary analysis. All RTIs 
were included in the models together (with the exception of PID which was modeled 
separately). 
As a secondary analysis to examine the association between RTI exposure severity 
and fibroid presence, we evaluated age- and multivariable-adjusted ORs of the association 
between the number of times diagnosed with each RTI and the presence of fibroids using 2 
indicator variables (1 vs. none; 2+ vs. none). Because of limited numbers of women reporting 
multiple infections, each separate RTI was modeled without adjusting for other RTIs. In 
addition, we looked at whether self-reporting more than 1 type of infection increased the 
odds of fibroids using 3 indicator variables (1 vs. none; 2 vs. none; 3+ vs. none). 
4.2.7.3 Sensitivity Analyses 
Syphilis was reported by too few women to analyze separately (n=15), but we 
repeated the primary analyses after excluding them to make sure they were not influential. 
Cervical treatment is an indicator of cervical lesions secondary to persistent HPV infection 
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and was found to be inversely associated with fibroids in our previous study
109
. Thus, the 
RTI associations we were investigating might be attenuated. Therefore, we repeated the 
primary analyses after excluding those who reported cervical treatment (n=229).  
4.3 Results 
Of the 1,696 women enrolled, 40 were excluded (34 reported never having sex and 6 
reported having HIV). Seventy percent (70%) of participants reported at least 1 RTI 
diagnosis (Table 3). Those with a prior history of an RTI, compared to women without one, 
tended to be older, more educated, heavier drinkers, parous, to have ever used Depo-Provera, 
to have more sex partners before age 20 years, and to have been younger at first sex (Table 
3). The prevalences of specific self-reported RTI diagnoses were: 10% for PID, 38% for CT 
and BV, 32% for trichomonas, 20% for gonorrhea, 9% for genital herpes, and 7% for genital 
warts (Suppl. Table 2). The median time since first diagnosis of any RTI was 9 years (IQR: 
5-13 years) (Supp1. Table 3). 
Twenty-two percent (22%) of women had fibroids discovered at ultrasound screening 
(Table 4). Of those with fibroids, the size of the largest fibroid was <2 cm for 62%; 63% had 
only 1 fibroid. The total fibroid volume was <2 cm
3
 for 52% of participants with fibroids.   
In primary analyses, age-adjusted and multivariable adjusted estimates were very 
similar (Table 4). Self-reported BV had a positive association with fibroids though not 
significant [aOR: 1.21 95% CI (0.93-1.58)].  In secondary analyses we examined size of the 
largest fibroid, number of fibroids and total fibroid volume as the outcomes (Figure 3). 
Women who reported any RTI had an elevated odds of a small fibroid [aOR: 1.31 95% CI 
(0.93-1.84)]. There was a 38% reduction in the odds of having 2 or more fibroids for CT 
[aOR: 0.62 95% CI (0.40-0.97)] and a 46% reduction for PID [aOR: 0.54 95% CI (0.25-
1.17)]. Those with a previous diagnosis of BV had a 47% increase in the odds of having 2 or 
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more fibroids [aOR: 1.47 95% CI (0.98-2.21)] and a 41% increase in the odds of having a 
larger total fibroid volume (≥2 cm3) [aOR: 1.41 95% CI (0.98-2.04)]. 
 In the secondary analyses that examined “severity” of RTI based on number of 
different RTIs we saw an increase in odds of fibroids for those with 2 RTIs [aOR: 1.41 95% 
CI (0.99-2.01)], but the odds was not elevated for those with 3 or more RTIs (Suppl. Table 
4). Multiple diagnoses of the same RTI were not associated with higher odds of fibroids 
(Suppl. Table 4).  
The first sensitivity analysis, exclusion of those with a self-reported diagnosis of 
syphilis (n=15), resulted in little change in associations between RTIs and fibroid presence 
(data not shown). However, the second sensitivity analysis, removal of those with a self-
reported diagnosis of cervical treatment (n=229), resulted in a somewhat stronger association 
for genital warts [aOR: 1.29 95% CI (0.76-2.18)]. Other RTI associations were essentially 
unchanged (data not shown).  
4.4 Discussion 
In this large study of young African-American women, there was little overall support 
for an association between women’s self-reported histories of RTIs and subsequent fibroid 
development. Even those having a history of three or more different RTIs or multiple 
diagnoses of the same RTI showed no indication of elevated odds of fibroids. However, our 
results for BV and CT are suggestive of possible associations with fibroids. Women reporting 
a history of BV had somewhat elevated odds of both small and large fibroids. The 
associations were of borderline significance for 2 or more fibroids and for larger total fibroid 
volume (≥2 cm3). Although speculative, the tendency for increased odds with BV might be 
influenced by its chronic nature 
111, 112
. For those with a previous CT diagnosis, the odds of 
having multiple fibroids (≥2) was significantly reduced. However, any mechanism for 
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protection by CT is unknown. In summary, our study results do not corroborate any of the 
suggestive increased odds of fibroids associated with self-reported histories of PID, CT, 
trichomonas or herpes previously described in smaller studies 
4, 5
. 
This study has several limitations. It was a cross-sectional analysis with self-reported 
RTI diagnoses. Though the onset of fibroid development is unknown, over half of the women 
reported their first RTI diagnosis before the age of 20, while fibroid development in African-
Americans appears to be infrequent before the mid-20s 
29
. Also, most of the fibroids were 
small suggesting relatively recent development. Finally, the median time between first RTI 
diagnosis and study enrollment was 9 years, again supporting the likelihood that exposure 
occurred before disease onset. 
Self-reported data on history of RTI diagnosis may be subject to recall error 
113-116
. 
However, the frequencies of RTIs in our sample are generally similar to those reported in 
other studies of African-American women 
117, 118
. Perhaps a more important problem is that 
the majority of RTIs can often be asymptomatic, so even those who have not had a previous 
diagnosis may still have had or currently have an RTI. Some women also may have been 
tested and were positive but never received their results, did not understand them or just did 
not report them (due to confidentiality concerns or social desirability bias). Because 
questions were asked via a self-administered CAWI questionnaire, social desirability bias 
should have been reduced 
119, 120
. The validity of our self-report data is supported by our 
observation that both lower age at first sex and higher numbers of partners were associated 
with increased reporting of infection. Finally, our sample is not a representative population-
based sample of women. However, because it captures early fibroid development (most of 
the women with fibroids had small fibroids), our sample was a relevant one for investigating 
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the possible role of RTIs in the hypothesized fibroid pathogenesis involving aberrant tissue 
repair 
102, 103
. 
Our study has several strengths. We used enrollment data from an ongoing 
prospective study with a standardized measure of fibroid status based on systematic 
ultrasound screening rather than fibroids clinically detected because of symptoms. The 
number, diameter and volume of the fibroids were systematically measured, so we were able 
to examine associations with these separate characteristics. Twenty-two percent (22%) of our 
cohort of young African-American women had fibroids at ultrasound screening, a prevalence 
which falls within the range of prior US studies that conducted ultrasound screening 
5, 6, 29, 30
. 
Our sample size was sufficient to provide good precision for the main hypotheses. We also 
had extensive data to assess potential confounding, very minimal missing data, and we 
conducted sensitivity analyses to evaluate potential bias.  
4.5 Conclusions 
Overall, the studies of RTIs and fibroids, including ours, reveal no strong 
associations. Our study was the first to look at the relationship between RTIs and fibroid size, 
number and total volume, but most studies have been limited by the use of self-reported 
exposure histories of these often asymptomatic infections. The small study that looked for 
pathogens in fibroid tissue did no serological assessment to biochemically measure past 
exposure to infection 
5
. Future studies are needed to take the next step and use serology to 
better investigate associations between RTIs and fibroids.  
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Table 3. Distribution of Covariates by Self-Reported Reproductive Tract Infection Status 
 
 Any Reproductive Tract Infection
a
 
Covariate 
Yes 
n = 1,172  
n (%) 
No 
n = 482 
n (%) 
Age     
    23-26  343 (29) 157 (33) 
    27-30  396 (34) 170 (35) 
    ≥31  433 (37) 155 (32) 
Education   
    ≤ High school/GED 229 (20) 133 (28) 
    Some college or     
    technical 
639 (55) 201 (42) 
    ≥ Bachelors 303 (26) 148 (31) 
Missing 1  
BMI (kg/m
2
)   
    15-24 212 (18) 111 (23)  
    25-29  266 (23) 78 (16) 
    30-34 236 (20) 84 (17) 
    ≥ 35 458 (39) 209 (43) 
Alcohol at age when drinking the most
b
   
    Low 255 (22) 172 (36)  
    Moderate 386 (33) 157 (33) 
    Heavy 531 (45) 153 (32) 
Parity   
    Nulliparous 409 (35) 218 (45) 
    Parous  763 (65) 264 (55) 
Depo-Provera   
    Never used 638 (54)  300 (62) 
    Ever used 534 (46) 182 (38) 
Age at menarche    
    7-10  206 (18) 96 (20) 
    11-19  966 (82) 386 (80) 
Sex partners before age 20   
    ≤1  203 (17) 190 (39) 
    2-5  588 (50) 237 (49) 
    ≥ 6   379 (32) 55 (11) 
Missing 2  
Age at 1
st
 sex   
    ≤14 407 (35) 83 (17) 
    15-16 426 (36) 143 (30) 
    ≥ 17  338 (29) 254 (53) 
Missing 1 2 
 
BMI, body mass index; GED, general education degree; IQR, interquartile range 
a
Includes pelvic inflammatory disease, chlamydia, bacterial vaginosis, trichomonas, gonorrhea, genital herpes, 
and genital warts; 2 participants not included because they responded “prefer not to answer” for at least 1 RTI 
and reported “No” for other RTIs; thus, their “any RTI” status could not be determined. 
b
Low drinkers were those who never had 10 or more drinks in a year. Heavy drinkers were those who usually 
drank 6 or more drinks on days when they drank or drank 4+ drinks per sitting at least 2 to 3 times a month. 
Moderate drinkers were all others.  
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Table 4. Adjusted Odds Ratios for Fibroids According to Self-Reported History of 
Reproductive Tract Infections 
 
 
Fibroids Age-adjusted 
Multivariable- 
adjusted 
Reproductive Tract 
Infections 
 
Yes 
n = 363 
n (%) 
No 
n = 1,293 
n (%) 
OR (95% CI) OR (95% CI) 
Any RTI
a
     
    Yes 262 (72) 910 (70) 
1.05 (0.80-1.36) 1.15 (0.87-1.52)
b
 
     No 101 (28) 381 (30) 
Missing  2   
PID     
    Yes 34 (9) 128 (10) 
 0.90 (0.60-1.35) 0.94 (0.62-1.43)
b
 
    No 329 (91) 1,164 (90) 
Missing  1   
Chlamydia     
     Yes 125 (34) 503 (39) 
0.85 (0.66-1.09) 0.92 (0.70-1.21)
c
 
     No 238 (66) 788 (61) 
Missing  2   
Bacterial Vaginosis     
     Yes 147 (41) 477 (37) 
1.14 (0.89-1.45) 1.21 (0.93-1.58)
c
 
     No 216 (60) 815 (63) 
Missing  1   
Trichomonas     
     Yes 116 (32) 414 (32) 
0.90 (0.70-1.16) 0.90 (0.68-1.20)
c
 
     No 247 (68) 878 (68) 
Missing  1   
Gonorrhea     
     Yes 62 (17) 261 (20) 
0.81 (0.60-1.11) 0.94 (0.67-1.33)
c
 
     No 301 (83) 1,031 (80) 
Missing  1   
Genital Herpes     
     Yes 31 (9) 112 (9) 
0.93 (0.61-1.42)       0.89 (0.58-1.39)
c
 
     No 332 (91) 1,180 (91) 
Missing  1   
Genital Warts     
     Yes 28 (8) 85 (7) 
1.10 (0.70-1.73) 1.09 (0.68-1.74)
c
 
     No 335 (92) 1,207 (93) 
Missing  1   
 
CI, confidence interval; OR, odds ratio; PID, pelvic inflammatory disease; RTI, reproductive tract infection
 
a
Includes pelvic inflammatory disease, chlamydia, bacterial vaginosis, trichomonas, gonorrhea, genital herpes, 
and genital warts  
b
Logistic regression model adjusted for age (continuous), education, body mass index, alcohol, menarche, 
parity, Depo-Provera use 
c 
Logistic regression model adjusted for age (continuous), education, body mass index, alcohol, menarche, 
parity, Depo-Provera use, and other RTIs except PID and the RTI being evaluated 
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RTI, reproductive tract infection 
a
Adjusted for age, education, body mass index, alcohol, menarche, parity, and Depo-Provera use 
b
Adjusted for age, education, body mass index, alcohol, menarche, parity, Depo-Provera use, and all other RTIs 
except PID and the RTI being evaluated 
 
Figure 2. Adjusted Odds Ratios for Size of the Largest Fibroid, Number of Fibroids and 
Total Fibroid Volume According to Self-Reported History of Reproductive Tract Infections 
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CHAPTER 5: HERPES SIMPLEX VIRUS-2 SEROPREVALENCE AND ULTRASOUND 
DIAGNOSED UTERINE FIBROIDS IN A LARGE POPULATION OF YOUNG 
AFRICAN-AMERICAN WOMEN
2
  
5.1 Introduction  
Uterine fibroids are one of the most common gynecologic conditions affecting 
women in the US during their reproductive years 
1
. Based on ultrasound screening of 
randomly selected women, the estimated cumulative incidence of fibroid tumors by age 50 is 
>80% for African-American women and close to 70% for White women 
6
. Symptoms 
resulting from fibroids (pain, severe bleeding, reproductive problems) are the leading reason 
for hysterectomy in the US, with the total annual costs of fibroids as high as $34 billion 
2
. 
Fibroids are hormonally dependent benign tumors of the uterine smooth muscle. 
Their etiologic causes are largely unknown, but established risk factors include African-
American heritage (African-Americans are 2 to 3 times as likely to have clinically 
recognized fibroids as White women 
6
), older age (up to the age of menopause), younger age 
at menarche, and nulliparity 
5, 20, 21
. Three studies have reported that progestin-only 
injectables (i.e. depot medroxyprogesterone acetate (DMPA)) are protective 
20, 27, 28
. Heavier 
alcohol use may be a risk factor, although the number of studies is small 
24, 25
.  
A hypothesis was postulated decades ago that RTIs may play a role in fibroid 
development 
3
. Both RTIs and fibroids disproportionately burden African-American women 
and certain RTIs can lead to conditions, e.g., chronic pelvic infection, that could result in 
                                                 
2
This whole chapter was taken from: Moore KR, Smith JS, Cole SR, et al. Herpes Simplex Virus-2 
Seroprevalence and Ultrasound Diagnosed Uterine Fibroids in a Large Population of Young African-American 
Women. American Journal of Epidemiology; In press. 
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inflammatory reactions 
3
. This hypothesis is consistent with another theorized mechanism of 
fibroid pathogenesis where infection can stimulate an inflammatory immune response which 
can facilitate the initiation of tissue damage resulting in tissue repair/regeneration (increased 
extracellular matrix, cell proliferation, decreased apoptosis), leading to the formation and 
growth of uterine fibroids 
102, 103
. Furthermore, fibroids were found to be associated with 
serologically-determined Chagas disease (caused by a protozoan parasite) 
96
, and EBV was 
found to infect smooth muscle cell tumors at sites outside of the uterus 
95, 96
.  
 However, the limited data that examine associations between RTIs and fibroid risk 
4, 
5, 121
, have yielded inconsistent findings. One of the primary aims for undertaking a large 
study of fibroids in African-American women, the SELF study was to fill this data gap 
122
. 
The data from prior studies suggested positive associations between fibroids and PID 
4
, CT 
4
, 
genital herpes 
5
, trichomonas 
5
, BV 
5, 121
 and syphilis 
5
. We recently published self-reported 
RTI data from SELF, showed no strong associations with fibroids (16). We did find that 
women reporting a history of bacterial vaginosis had somewhat elevated odds of multiple 
fibroids (>2) and larger total fibroid volume (≥2 cm3) and women reporting a history of CT 
tended to have fewer and smaller fibroids 
121
. However, all of these previous reports 
measured RTI history with questionnaire data, which can be plagued by recall error as well 
as misclassification due to the asymptomatic nature of most RTIs 
113-116
. An immunological 
measure of exposure namely serology (diagnostic identification of antibodies in the serum 
that remain after infection), would provide a more nearly accurate assessment of exposure 
than self-reported RTI history.  
 HSV-2, the main cause of genital and neonatal herpes, is a common RTI in the US 
50
. 
Compared to women of other racial/ethnic groups in the US, African-American women have 
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the highest seroprevalence of HSV-2 (50% for 14-49 year-olds between 2007-2010) 
55
. Other 
main risk factors for HSV-2 include: higher numbers of sexual partners, heavy alcohol use, 
low socioeconomic status, being unpartnered vs. married/cohabiting and lack of consistent 
condom use 
55, 79-83
. Also, DMPA use may increase risk of HSV-2 seroconversion 
84, 85
, and 
age at menarche has been found to be associated with HSV-2 
86
 and has been identified as a 
predictor of sexual behavior which is highly associated with HSV-2 
87, 88
. 
  HSV-2 antibodies have been shown to persist for years post-infection 
123, 124
, and 
serologic testing for HSV-2 can be done sensitively and specifically for past exposure to 
HSV-2 
125
. Cell culture and polymerase chain reaction are the recommended laboratory tests 
for people who have active lesions or ulcers present 
126
. However, most HSV-2 infections are 
asymptomatic or unrecognized (over 85% of seropositive African-American women reported 
no history of diagnosis) 
55
; thus, seropositivity to HSV-2 is the best estimate of past, 
cumulative exposure 
55, 79
.  
Building upon previous work which found a positive association between self-
reported HSV-2 and fibroids 
5
, our primary aim was to investigate the relationship between 
HSV-2 and fibroids in a large cohort with ultrasound screening for fibroids and serological 
measurement of exposure. This study was the first to investigate the association of fibroids 
with HSV-2 exposure assessed serologically. We hypothesized that women seropositive to 
HSV-2 would have a higher prevalence of fibroids than women seronegative to HSV-2. We 
also explored the relationship between HSV-2 seropositivity and number, size, and total 
volume of fibroids. 
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5.2 Methods 
5.2.1 Study Participants and Data Collection  
We used transvaginal ultrasound results, self-reported questionnaire data and stored 
frozen serum specimens from participants in SELF, an ongoing study based in the Detroit, 
Michigan area. SELF is a prospective cohort study of fibroid development. Enrollment data 
and specimen collection protocols have been described previously 
122
. In brief, from 
November 2010 to December 2012, the study recruited 1,696 African-American women 
volunteers ages 23-34. Women were not eligible for SELF if they had previously been 
diagnosed with uterine fibroids; had had a hysterectomy; had ever taken medication to treat 
lupus, Grave's disease, Sjogren's scleroderma, or multiple sclerosis; or had ever had any type 
of cancer treated with radiation or chemotherapy. The study was approved by the institutional 
review boards of NIEHS and HFHS.  
5.2.2 Fibroid Assessment 
Transvaginal ultrasound, the standard procedure for the detection and diagnosis of 
fibroids, was used in this study 
16
. Fibroids were assessed by study sonographers as described 
previously 
122
 at one of three clinics. Focal fibroids of 0.5 cm diameter or greater were 
measured in triplicate. For each measurement, the 3 perpendicular diameters (longitudinal, 
anterior-posterior and transverse) were recorded.   
5.2.3 Outcome Definitions 
 The primary outcome of this study was fibroid presence (yes/no) at the transvaginal 
ultrasound examination completed at enrollment. Fibroids classified as “questionable” were 
those where at least one diameter could not be measured. Participants with at least one 
fibroid or questionable fibroid ≥0.5 cm in diameter at enrollment ultrasound were considered 
to have fibroids, and all women without a fibroid or questionable fibroid ≥ 0.5 cm in 
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diameter were considered not to have fibroids. The secondary outcomes for this analysis 
were size of the largest fibroid, number of fibroids, and total fibroid volume. The size of the 
largest fibroid was estimated by averaging the maximum diameter (longitudinal, anterior-
posterior or transverse) of each of the triplicate fibroid measurements. Fibroid volume (cm
3
) 
was measured by computing the volumes of each of the triplicate fibroid measurements using 
the ellipsoid formula (longitudinal x anterior-posterior x transverse x 0.5233), and averaging 
across the three volumes. Total fibroid volume (cm
3
) was calculated by adding the average 
volumes from each of a woman’s fibroids. Total fibroid volume was not computed for 
women with only questionable fibroids (n=6) because at least one diameter was not 
measured.  
5.2.4 HSV-2 Assessment 
HSV-2 antibody serostatus was assessed by the International Sexually Transmitted 
Diseases Research Laboratory at Johns Hopkins University using the Focus Diagnostics 
HerpeSelect® 2 Enzyme-Linked Immunosorbent Assay (Focus Diagnostics, Cypress, 
California) per package instructions 
127
. This type-specific assay to glycoprotein gG2 allows 
for the qualitative detection of HSV-2 immunoglobulin G antibodies with or without the 
presence of HSV-1 
127
. Antibody levels of >1.10 optical density units were categorized as 
seropositive and levels <0.90 were seronegative. Levels ≥0.9 and ≤1.10 were indeterminate 
and were retested. The level of antibody response cannot be used to determine active 
infection or recency of initial infection.    
 For quality control, we included blinded duplicate samples. Aliquots were created 
from unused serum samples collected from SELF participants during a special blood draw 
six months after enrollment 
122
. Two aliquots from each of 42 specimens served as 84 blinded 
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controls. Forty of the 42 duplicate pairs had identical results. For each of the other two 
discordant pairs, one of the aliquots was considered indeterminate. The result for the other 
aliquot of each of these two discordant pairs matched the result found for the enrollment 
specimen from the same participant. 
5.2.5 Statistical Analyses 
Due to the use of telephone and web-based interview methods which did not allow 
participants to skip questions, there was minimal missing data on covariates. However, 
participants were able to respond “prefer not to answer.” This response (<1%) was coded as 
missing, and complete case analysis was performed. Variables were categorized based on the 
distribution of the data and comparability with the literature. All analyses were completed on 
women who had blood samples taken at enrollment. Standard descriptive statistics were 
performed for all variables of interest. We also described the relationship between HSV-2 
serostatus and number of sexual partners and age at first intercourse for comparison with the 
literature. All analyses were conducted with SAS 9.3 (SAS Institute, Inc., Cary, NC).  
5.2.5.1 Primary Analyses  
 Logistic regression was used to compute ORs and 95% CIs to evaluate the 
relationship between HSV-2 serostatus and fibroid presence. Although the relative odds will 
overestimate the relative risk for associations with an outcome as common as fibroids, 
overestimation is minimal for weak associations and in any case does not affect statistical 
tests. Potential confounders and variables of interest were determined based on a review of 
the literature, and a directed acyclic graph 
106
 was used to provide a conceptual framework. 
Potential confounders included: age in years (continuous), age at menarche (7 to 10, 11 to 19 
years), alcohol (low, moderate, heavy), and use of DMPA (ever, never). The alcohol variable 
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reflected the drinking level each woman reported for the age(s) when she was drinking the 
most. Low drinkers were those who never had 10 or more drinks in a year. Heavy drinkers 
were those who usually drank 6 or more drinks on days when they drank or drank 4+ drinks 
per sitting at least 2 to 3 times a month. Moderate drinkers were all others. Variables of 
interest based on the literature included education (high school/general education 
development or less, some college/associates/technical, bachelors/masters/doctorate) and 
body mass index (15-24, 25-29, 30-34, ≥35) in kg/m2; parity (nulliparous, parous) was 
included to increase precision because of the consistent association between parity and 
fibroids in the literature. We included age, age at menarche, parity, and DMPA use in a full 
model a priori. The alcohol variable was not included a priori because the amount of 
literature supporting an alcohol and fibroid association is small. After adding alcohol and the 
additional variables of interest, we used backwards elimination and the 10% change in 
estimate approach to determine the minimally adjusted final model. Only the covariates 
included a priori remained in the final model.  
5.2.5.2 Secondary Analyses 
 As a secondary analysis we examined the association between HSV-2 and fibroid 
characteristics: size of the largest fibroid, number of fibroids and total fibroid volume. 
Medians rounded to the nearest whole number were used to determine category cut points for 
size of the largest fibroid and total fibroid volume (2 cm and 2 cm
3
, respectively). To 
estimate the ORs and 95% CIs for the association of HSV-2 serostatus and fibroid size, 
number and total volume, we used multinomial logistic regression. Moreover, because the 
majority of HSV-2 infections are asymptomatic, self-reported infections are likely to be those 
that are symptomatic. Thus, as a secondary analysis, we evaluated the multivariable-adjusted 
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ORs and 95% CIs between HSV-2 and fibroid presence using a 3-level exposure variable: 
0=seronegative, 1=not symptomatic (seropositive with no self-reported diagnosis), and 
2=symptomatic (seropositive with self-reported diagnosis). For both of these secondary 
analyses we adjusted for the same confounders as in the final model in the primary analysis 
(age, age at menarche, parity, and DMPA use). 
5.2.5.3 Sensitivity Analyses 
 To evaluate the robustness of our findings, we examined multivariable-adjusted ORs 
and 95% CIs for the association of HSV-2 with fibroids in a series of sensitivity analyses by 
restricting or stratifying the sample. Cervical treatment is an indicator of cervical lesions 
secondary to persistent human papillomavirus infection and was found to be inversely 
associated with fibroids in a previous study 
109
. Thus, any HSV-2 associations we observed 
might be attenuated. Therefore, we repeated the primary analyses after excluding those who 
reported cervical treatment (n=231 excluded). To evaluate age as an effect modifier (due to 
possible decline in antibodies over time), we looked at the association between HSV-2 and 
fibroid presence within two age strata (23 to 29 years, 30 to 35 years).  
 To investigate temporality of HSV-2 exposure in relation to fibroid development, we 
looked at the association between HSV-2 and fibroids among strata of size of the largest 
fibroid (<2 cm and ≥2 cm). Those with smaller fibroids are more likely to have developed 
fibroids more recently and thus, may be more likely to have had exposure to HSV-2 before 
fibroid development compared to women with larger fibroids. In addition, we looked at the 
association of HSV-2 and fibroid presence within 2 strata of number of sexual partners 
before age 20 (0 to 1 sex partner, 2 or more sex partners). Those with more sexual partners 
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before the age of 20 would have been more likely to be exposed to HSV-2 prior to fibroid 
development. 
 A total of 1,696 women were enrolled in the SELF study. HSV-2 serology was 
conducted for the 98% of participants with available enrollment blood samples (n=1,662). 
Four of the samples had indeterminate results that were excluded. Therefore, our analyses 
were performed on the 1,658 participants with HSV-2 serology results.  
5.3 Results 
The median age of our cohort at enrollment was 29 years, the median age at menarche 
was 12 years, the majority were parous, and over 40% had ever used DMPA. Forty-seven 
percent (n=869) of the participants were seropositive for HSV-2. HSV-2 seropositive women 
tended to be older, to be less educated, to be heavier drinkers, to be parous, to be more likely 
to have ever used DMPA, to have more sex partners before age 20, and to have been younger 
at first sex compared to those who were seronegative for HSV-2 (Table 5).  
Twenty-two percent of women had fibroids discovered at ultrasound screening (Table 
6). Of those with fibroids, the size of the largest fibroid was <2 cm for 61%; 63% had only 1 
fibroid. The total fibroid volume was <2 cm
3
 for 51% of participants with fibroids.   
In primary analyses, the odds of fibroids was similar for those who were HSV-2 
seropositive and seronegative, in both age- and multivariable-adjusted models (multivariable- 
adjusted, aOR: 0.94 95% CI: 0.73, 1.20) (Table 6). In secondary analyses we examined size 
of the largest fibroid, number of fibroids, and total fibroid volume as the outcomes (Figure 
4). There was no significant association with HSV-2 exposure and fibroid size, number or 
total volume.  
We also examined symptomatic herpes and fibroid presence based on a combination 
of self-reported genital herpes and serology data (Table 7). Only 16% of those who were 
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seropositive for HSV-2 actually self-reported having had a genital herpes diagnosis 
(sensitivity for self-reported HSV-2 exposure). However, 98% of those who were 
seronegative self-reported no diagnosis of genital herpes (specificity). Those who were 
seropositive and self-reported an HSV-2 diagnosis (our measure of symptomatic herpes) did 
not have a higher odds of fibroids. Furthermore, the lack of an association between HSV-2 
and fibroids remained consistent across the sensitivity analyses performed (Table 8). 
5.4 Discussion 
Our study did not show an association between HSV-2 and fibroid presence, size, 
number or total volume. Even among women who were seropositive and had genital herpes 
severe enough to self-report a clinical diagnosis, there was no association with fibroids. In 
addition, the lack of an association was consistent across various sensitivity analyses: 
excluding women with cervical treatment, and stratifying by size of the largest fibroid, age, 
and number of sex partners before age 20.  
Our findings are consistent with a previous report in this same population looking at 
several self-reported RTIs, which showed no association of genital herpes with fibroids 
121
. 
Two other studies have investigated the association between self-reported genital herpes and 
fibroid presence 
4, 5
. A clinic-based case-control study of 18-55 year-old pre-menopausal 
women showed no association of genital herpes with clinically detected fibroids 
4
. The UFS 
5
, a cross-sectional study that used ultrasound to screen randomly- selected members of an 
urban health plan aged 35-49 years for fibroids, found suggestions of a positive association 
of self-reported genital herpes with fibroids in both African-American and White women 
5
. 
However, these findings were not precise enough to rule out associations due to chance. A 
small pilot study investigated whether pathogens were present in fibroid tissue;  specimens 
from 20 UFS participants who had reported a history of sexually transmitted disease or 
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multiple sex partners were tested for viral DNA to HSV-1 and HSV-2, cytomegalovirus, 
human herpes virus 6,7,8 and EBV 
5
 using PCR. None of these pathogens was detected in the 
tumor samples.  
Our study has several limitations. It was a cross-sectional analysis. Thus, the 
acquisition of HSV-2 infection in relation to fibroid development is unknown. However, it is 
likely that exposure occurred before disease onset for most women. Over half of the women 
who self-reported genital herpes reported that their first diagnosis was before the age of 22 
and approximately 45% of new HSV-2 infections in the US are among 15-24 year olds 
50
. 
Also, most of the fibroids were small suggesting relatively recent development, and fibroid 
development in African-Americans appears to be infrequent before the mid-20s 
29, 122
. 
Finally, the median time between first self-reported HSV-2 diagnosis and study enrollment 
was 6 years, and because antibody titers persist for years post-infection 
123, 124
, even exposure 
to HSV-2 multiple years prior to enrollment should be captured.  
 We did not use the Western blot, the gold standard method for HSV-2 serology 
125, 
128
. However, the HerpeSelect® 2 assay we used 
127
 has been found to perform very well for 
HSV-2 infections, with sensitivity between 96-100% and specificity between 97-98% 
129, 130
 
compared to the Western blot. The Western blot is not US Food and Drug Administration 
approved and is more complex, costly, less time efficient and much less widely available 
compared to the enzyme-linked immunosorbent assay 
131
. In addition, we did not capture 
those who have very recent infection because it can take weeks to months after infection for 
immunoglobulin G antibodies to be detected. However, because we seek to measure past 
exposure, ideally at the time of fibroid development, low sensitivity for very recent infections 
did not jeopardize our assessment of cumulative exposure to HSV-2.  
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 In addition, HSV-2 seroprevalence alone underestimates the prevalence of genital 
HSV infection due to the omission of genital infections caused solely by HSV-1 which are 
increasing 
132
. However, because HSV-1 also causes orolabial infections which are very 
prevalent 
132
, a large proportion of the population will have antibodies to HSV-1 and we 
would not be able to distinguish orolabial from genital HSV-1 infection. Thus, the value of 
the added information to be gained from measuring HSV-1 is unclear. 
 Lastly, our sample is a volunteer sample of women. However, the seroprevalence of 
HSV-2 in our cohort (47%) was very similar to the seroprevalence of 50% for African-
American women in the US 
55
. Furthermore, 22% of our cohort had fibroids at ultrasound 
screening, which falls within the range of prior US studies that conducted ultrasound 
screening 
5, 6, 29, 30
.  
Our study also had several strengths. This was the first study to investigate the 
relationship between HSV-2 and fibroids using an immunological measure of exposure. Our 
blinded quality control samples demonstrated low measurement error in HSV-2 serostatus. 
Previous studies have used only self-reported diagnosis of genital herpes as the exposure 
measurement, which is problematic due to the high prevalence of asymptomatic infection. 
Furthermore, we used a standard and valid measure of fibroid status based on systematic 
ultrasound screening rather than fibroids clinically detected because of symptoms or 
incidental detection. The number, diameter, and volume of the fibroids were systematically 
measured, so we were able to examine associations with these separate characteristics. Our 
sample size was sufficient to provide good precision for the main hypotheses. In addition, 
most women with a history of HSV-2 are unaware of their exposure status making it very 
unlikely that women without fibroids who had a history of HSV-2 exposure would be more 
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likely to enroll than those without HSV-2; thus, there is limited potential for selection bias. 
Our study also had extensive data to assess potential confounding, minimal missing data, and 
sensitivity analyses to evaluate potential bias. 
 Overall, based on our findings in a large cohort of African-American women, HSV-2 
seropositivity does not appear to be a risk factor for fibroids in this 23-34 year-old age group. 
However, this does not suggest that other RTIs do not play a role in fibroid development. 
Further study of other serologically measured RTIs is still warranted, as are prospective 
studies on the relationship between RTIs and fibroid growth.  
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Table 5. Herpes Simplex Virus Type 2 Serostatus, Stratified by Selected Enrollment 
Characteristics of 1,658 23-34 Year-Old African-American Women in the Study of 
Environment Lifestyle and Fibroids, Detroit Metropolitan Area, Michigan, 2010-2012 
 
 HSV-2 Seropositive 
N=1,658 
Covariate 
Yes 
n = 789   
No 
n = 869  
n % n % 
Age, years     
    23-26  191  24 319  37 
    27-30  284  36 286  33 
    31-35
a
  314  40 264  30 
Education     
    ≤ High school/GED 235  30 129  15 
    Some college or technical 409  52 423  49 
    ≥ Bachelors 144  18 317  36 
     Missing                 1    
BMI
b
      
    15-24 164  21 164  19 
    25-29  157  20 186  21 
    30-34 141  18 177  20 
    35-80 327  41 342  39 
Alcohol at age when drinking the most
c
     
    Low 198  25 240  28 
    Moderate 231  29 309  35 
    Heavy 360  46 320  37 
Parity     
    Nulliparous 238  30 412  47 
    Parous  551  70 457  53 
DMPA     
    Never used 383  49 566  65 
    Ever used 406  51 303  35 
Age at menarche, years     
    7-10
d
 157  20 142  16 
    11-19  632  80 727  84 
Sex partners before age 20      
    ≤1e  154  19 268  31 
    2-5  399  51 413  48 
    ≥ 6   234  30 187  21 
   Missing 2  1  
Age at 1
st
 intercourse, years     
    ≤14 284  36 196  23 
    15-16 274  35 287  33 
    ≥ 17e 231  29 383  44 
    Missing 0  3  
 
Abbreviation: BMI, body mass index; DMPA, depot medroxyprogesterone acetate; GED, general education 
development; HSV-2, herpes simplex virus type 2. 
a 
No one over 34 was recruited, but some 34 year-olds had turned 35 by the time they had their ultrasound 
examination. 
b
BMI given as kg/m
2
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c
Low drinkers were those who never had 10 or more drinks in a year. Heavy drinkers were those who usually 
drank 6 or more drinks on days when they drank or drank 4+ drinks per sitting at least 2 to 3 times a month. 
Moderate drinkers were all others. 
d
Categorized to identify early age at menarche, the category associated with fibroids. 
e
Includes participants who reported never having sex. 
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Table 6. Herpes Simplex Virus Type 2 Serostatus in Relation to Fibroids among 1,658 23-34 
Year-Old African-American Women in the Study of Environment, Lifestyle and Fibroids, 
Detroit, MI Metropolitan Area, 2010-2012: Odds Ratios and 95% Confidence Intervals 
 
 
N 
 
Have 
Fibroids 
Age-
Adjusted 
OR  
95% CI Multivariable- 
Adjusted
a
 
OR  
95% CI 
n % 
HSV-2 
Seropositive 
       
    No  869 195  22 1.00 referent 1.00 referent 
    Yes  789 170  22 0.82 0.64, 1.04 0.94 0.73, 1.20 
Abbreviation: CI, confidence interval; HSV-2, herpes simplex virus type 2; OR, odds ratio. 
a
Adjusted for age, age at menarche, depot medroxyprogesterone acetate use, and parity. 
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Table 7. Symptomatic and Asymptomatic Serologically-Detected Herpes Simplex Virus 
Type 2 in Relation to Fibroids among 1,658 23-34 Year-Old African-American Women in 
the Study of Environment, Lifestyle and Fibroids, Detroit, Michigan Metropolitan Area, 
2010-2012: Odds Ratios and 95% Confidence Intervals 
 
HSV-2
a
 
N Have Fibroids OR
b
 95% CI 
n % 
Seronegative 853 189  22 1.00 referent 
Symptomatic
c
      
        No 664 146  22 0.99  0.76, 1.29 
        Yes 124 24  19 0.77  0.47, 1.26 
Abbreviation: CI, confidence interval; HSV-2, herpes simplex virus type 2; OR, odds ratio
.
 
a
Limited to participants with data on HSV-2 symptomatology; 17  participants had missing data: 1 with 
missing data on self-reported genital herpes and 16 who self-reported genital herpes but were HSV-2 
seronegative. 
b
Adjusted for age, age at menarche, depot medroxyprogesterone acetate use, and parity. 
c
Defined as participants who were HSV-2 seropositive who self-reported having been diagnosed with genital 
herpes (“Yes”) or self-reported not having been diagnosed with genital herpes (“No”). 
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Table 8. Sensitivity Analyses of the Association of Fibroids with Herpes Simplex Virus Type 
2 Serostatus among 1,658 23-34 Year-Old African-American Women in the Study of 
Environment, Lifestyle and Fibroids, Detroit, Michigan Metropolitan Area, 2010-2012: Odds 
Ratios and 95% Confidence Intervals 
 
 N OR
a
 95% CI 
Full sample 1,658 0.94 0.73, 1.20 
Excluding 
women with 
prior cervical 
treatment 
1,426 0.95 0.72, 1.24 
Stratified by 
age, years 
   
     23-29 934 0.84 0.58, 1.22 
     30+ 724 1.01 0.72, 1.41 
Stratified by 
size of largest 
fibroid, cm 
   
<2 vs. none 224 vs. 1,293 0.88         0.65, 1.18 
≥2 vs. none 141 vs. 1,293 1.06         0.73, 1.54 
Stratified by 
number of sex 
partners 
before age 20
b
  
   
     0 to 1  422 0.99 0.60, 1.64 
     2+  1,233 0.91 0.68, 1.21 
  Abbreviation: CI, confidence interval; OR, odds ratio. 
   a
Adjusted for age, age at menarche, depot medroxyprogesterone acetate use, and parity. 
b
3 participants had missing data for number of sex partners before age 20. 
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Figure 3. Size of largest fibroid, number of fibroids, and total fibroid volume in relation to 
herpes simplex virus type 2 (HSV-2) serostatus among 365 23-34 year-old African-American 
women with fibroids in the Study of Environment Lifestyle and Fibroids, Detroit, Michigan 
metropolitan area, 2010-2012: odds ratios (ORs) and 95% confidence intervals (CIs) adjusted 
for age, age at menarche, depot medroxyprogesterone acetate use, and parity. 
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CHAPTER 6: CONCLUSIONS 
 In summary, we investigated possible associations of uterine fibroids with past 
exposure to self-reported RTIs and with HSV-2 measured with standard serological methods. 
We used enrollment data from an ongoing prospective study with a standardized measure of 
fibroid status based on systematic ultrasound screening. We had extensive data to assess 
potential confounding, minimal missing data and conducted sensitivity analyses to evaluate 
potential bias. The study for Aim 2 was the first to investigate the association of uterine 
fibroids with RTI exposure assessed serologically. The results of these studies revealed no 
strong evidence for a relationship between RTIs and fibroids. 
6.1 Limitations 
This project had several limitations. The two studies have a cross-sectional design, 
thus the timing of both infection and fibroid development was unknown. However, in this 
study population, over half of the women reported their first diagnosis of any RTI before age 
20 and genital herpes before the age of 22 while fibroid development in African-Americans 
appears to be infrequent before the mid-20s. Also, the median time between first RTI 
diagnosis and study enrollment was 9 years. In addition, most of the fibroids were small 
suggesting relatively recent development. All of these factors support the likelihood that 
exposure occurred before disease onset. 
For Aim 1 of our study, we used self-reported exposure data on history of RTI 
diagnosis which could be subject to recall error 
113-116
. The majority of RTIs are 
asymptomatic so even those who have not had a previous diagnosis may still have had or 
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currently have an RTI. In addition, some women may have been tested and were positive but 
never received their results, did not understand them or just did not report them (due to 
confidentiality concerns or social desirability bias). Therefore, misclassification due to 
underreporting could result. However, the misclassification should be non-differential 
because it should not differ by fibroid status (no one was diagnosed with fibroids prior to the 
study and, in most cases, the questions on RTIs were administered before enrollment 
ultrasound). In addition, the questions were asked via a self-administered computer assisted 
web interviewing (CAWI) questionnaire; therefore, an interviewer was not present, which 
should help to minimize social desirability bias and improve reporting 
119, 120
.  
 For Aim 2, serological detection of infection as a measure of lifetime exposure has 
its limitations. Type-specific HSV-2 seroprevalence alone underestimates the prevalence of 
genital HSV infection due to the omission of genital infections caused solely by HSV-1 (30-
50%) 
132, 133
. There has been an increase in genital HSV-1 infections over time which is 
possibly due to declines in early childhood acquisition of HSV-1 
132
 leading to more young 
people who are susceptible to genital HSV-1 and/or increases in oral-genital contact among 
adolescents 
133
.  
 As stated previously, HSV-1 and HSV-2 have an intricate relationship. 
Symptomatic HSV-2 disease is more likely among persons lacking HSV-1 antibodies and 
acquisition of HSV-1 among persons with prior HSV-2 infection is rare 
93
. Prior oral labial 
HSV-1 appears to protect against the acquisition of genital HSV-1 disease.  However, genital 
or oral HSV-1 does not protect against HSV-2 acquisition 
93
. Furthermore, because HSV-1 
also causes orolabial infections, a large proportion of the population would have antibodies to 
HSV-1 and we would not be able to distinguish orolabial from genital infection. If persons 
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are seronegative for HSV-2 but self-report a diagnosis of genital herpes, a seropositive HSV-
1 result could indicate genital HSV-1 infection, incorrect diagnosis, incorrect recall of 
diagnosis, HSV-2 assay error (false negative) or lack of HSV-2 antibody persistence. Thus, 
given the complexity of the relationship and our lack of prospective data on infection, the 
value of the added information to be gained from measuring HSV-1 is unclear. 
We also did not have clinical measures of symptomatic infection or frequency of 
recurrences for HSV-2 which could all be important factors leading to more inflammation. 
However, for HSV-2, we did explore whether those who were seropositive and self-reported 
a diagnosis of infection had an elevated OR compared to those who are only seropositive 
because those who self-report diagnosis may be more likely to have symptomatic infection. 
In regards to HSV-2, the more symptomatic the primary infection, the more recurrences and 
the more symptomatic recurrences 
91
. In addition, we looked at the self-reported information 
on the number of times diagnosed with infection and the number of RTIs, which could shed 
some light on the relationship between reinfection or recurrences and fibroid risk. 
This was also a volunteer sample of women; we did not have a representative 
population-based sample, thus there is potential for selection bias. All of these women had 
never been diagnosed with fibroids and thus may have a more asymptomatic condition. 
However, the symptoms related to fibroids especially heavy menstrual bleeding and pain 
overlap with other conditions and some women may not know that these symptoms signal 
any condition other than being a woman. Thus, these women are not necessarily more 
asymptomatic but may not have sought care or treatment for their symptoms. However, we 
may have selected for women with more asymptomatic fibroids because they have not been 
diagnosed. We found null associations while other studies found suggestions of positive 
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associations. The past studies were among older women who had larger fibroids and the 
Faerstein et al.
4
 study only looked at clinically recognized fibroids which are most likely 
larger and more symptomatic; in contrast, most fibroids in our population were small; thus, 
the past studies could be looking at a different aspect of the relationship between RTIs and 
fibroids such as growth vs. initiation. Because our sample captures early fibroid development 
(most of the women with fibroids had small fibroids), it was most relevant for investigating 
the role of RTIs in fibroid initiation. However, our study did include 51 (13% of those with 
fibroids) women with large fibroids (>=4 cm), and we did look at the association between 
RTIs and size of fibroid and total fibroid volume and did not see any suggestions of positive 
associations. 
In addition, because women had to have never been diagnosed with fibroids to enter 
the SELF study, there could have been women that did not enter the study because they had a 
previous diagnosis of fibroids and these women may have been more likely to have been 
exposed to HSV-2. Thus, below is a scenario based on an estimate of the number of women 
who would have been diagnosed with fibroids before being offered participation in the SELF 
study. We sought to determine what proportion of them would have had to be seropositive 
for HSV-2 in order for their inclusion to have changed the null association we observed to a 
strong enough positive association to change our conclusion.  
 A prior ultrasound screening study indicated that approximately 30% of black women 
ages 25-34 years with ultrasound-confirmed fibroids report a prior fibroid diagnosis
134
. Based 
on that data, we assumed that 30% of women in our target population who had fibroids 
(denoted y) were not included in the observed SELF dataset (n=365 women with 
undiagnosed fibroids in the data set). Given this assumption, the expected total number of 
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women with fibroids in SELF if this study sample had included women with a prior fibroid 
diagnosis (denoted x) would be equal to 365 + y. We solved for x and y: 
o x-x(0.30)=365 
o x=521, representing the expected number of women with fibroids in SELF if 
the study sample had included women with previously-diagnosed fibroids and 
30% were missing due to the exclusion 
o x-365=y 
o y=156, representing the expected number of women with prior clinically-
diagnosed fibroids that were excluded from entry into SELF  
The calculations above were similar to those in the sensitivity analysis in Upson et al., 2015 
135
. 
 In order to determine what percentage of these 156 women would have had to be 
seropositive for HSV-2 in order for us to have found a strong enough positive association 
between HSV-2 and fibroid status to change our conclusion, we computed the crude odds 
ratio (OR) and 95% CIs for varying prevalences of seropositivity, ranging from 50% to 100% 
(Table 9).  
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Table 9. Effect of Potential Selection Bias Due to Exclusion of Women Previously 
Diagnosed with Fibroids.  Crude Odds Ratios for Fibroids According to HSV-2 Serostatus 
assuming Varying HSV-2 Seroprevalence among an estimated 156 Women with Fibroids 
Excluded from Entry into SELF 
 
HSV-2 seroprevalence in 
156 women with previously-
diagnosed fibroids 
OR for fibroids in 
relation to HSV-2 
serostatus  
95% CI 
50% 0.99 0.81-1.21 
55% 1.05 0.85-1.28 
60% 1.12 0.91-1.36 
65% 1.18 0.96-1.45 
70% 1.26 1.02-1.54 
75% 1.34 1.09-1.64 
80% 1.42 1.15-1.73 
 
 CI, confidence interval; HSV-2, herpes simplex virus type 2; OR, odds ratio 
  
 Based on the above crude calculations, at least 70% of the women who were excluded 
due to having been previously diagnosed with fibroids would have had to be seropositive for 
HSV-2 in order to have an OR of 1.3 or higher. Given that this proportion is much higher 
than the seroprevalence of HSV-2 among African-American women in the US (50%)
55
, it is 
unlikely that exclusion of women with previously diagnosed fibroids resulted in selection 
bias strong enough to produce the observed result. Also, these estimates are not adjusted for 
age which is a confounder because increasing age is a risk factor for both prevalence of 
fibroids and HSV-2 seropositivity (among women without fibroids) in SELF. Thus, the 
women excluded because they already had a fibroid diagnosis would most likely be, on 
average, older than the women in the study and be more likely to have been exposed to HSV-
2, so the adjusted estimates would be closer to the null. 
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6.2 Strengths 
This project had several strengths. We used enrollment data from an ongoing 
prospective study with a standardized measure of fibroid status based on systematic 
ultrasound screening rather than fibroids clinically detected because of symptoms. The 
diameter and volume of the fibroids were systematically measured, so we were able to 
examine the association with small as well as large fibroids and total volume. In addition, we 
measured our exposure using standard serological methods (for Aim 2) rather than self-report 
and our sample size was sufficient to provide good precision for the main hypotheses. 
Twenty-two percent (22%) of our cohort of young African-American women had fibroids at 
ultrasound screening, a prevalence which falls within the range of prior US studies that 
conducted ultrasound screening 
5, 6, 29, 30
. We also had extensive data to assess potential 
confounding. Our population is comprised of young, African-American women. Thus, our 
population inherently accounts for some of the biggest confounders (African-American 
heritage and age), so we did not have to adjust for them. We also had information on other 
potential confounders such as Depo-Provera and alcohol use which the previous studies did 
not adjust for. In addition, we had minimal missing data and conducted sensitivity analyses to 
evaluate potential bias. 
6.3 Public Health Implications 
 Overall, based on our findings in a large cohort of African-American women, HSV-2 
seropositivity does not appear to be a risk factor for fibroids in this 23-34 year-old age group. 
Thus, HSV-2 serostatus does not help to predict women at high risk of fibroids and any 
systemic or uterine inflammation associated with HSV-2 infection does not appear to 
increase risk of fibroids. Furthermore, we did not find any strong associations between self-
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reported RTIs and fibroid presence, number, size or total volume. However, our findings for 
CT and BV warrant further investigation.  
6.4 Future Research 
 Further study of other serologically measured RTIs is still warranted, as are 
prospective studies of the impact of RTIs on fibroid growth. We are currently in the process 
of collecting serology data on CT in the SELF study cohort in order to further investigate the 
relationship with fibroids similar to Aim 2 in this project. In addition, the SELF study is a 
prospective study. Almost 80% of the participants did not have fibroids at enrollment, and 
because vaginal swabs, urine and blood were collected at enrollment, there is potential to 
investigate RTIs as a risk factor for fibroid incidence in this cohort as well.  
 
  
70 
APPENDIX 1: DIRECTED ACYCLIC GRAPH 
 
Appendix Figure 1. Directed Acyclic Graph of the Relationship between Herpes Simplex 
Virus-2 and Fibroids 
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APPENDIX 2: CHAPTER 2 SUPPLEMENTAL TABLES 
Supplemental Table 1. Age-Adjusted Correlation Coefficients among Self-Reported Reproductive Tract Infections 
 
Spearman Partial Correlation Coefficients 
N = 1,653 
Reproductive Tract 
Infections
a
 
Chlamydia 
Bacterial 
Vaginosis 
Trichomonas Gonorrhea 
Genital 
Herpes 
Genital 
Warts 
Chlamydia 1      
Bacterial Vaginosis 0.20 1     
Trichomonas 0.24 0.24 1    
Gonorrhea 0.31 0.13 0.23 1   
Genital Herpes 0.08 0.12 0.08 0.09 1  
Genital Warts 0.05 0.07 0.07 0.04 0.11 1 
 
a
PID is not included because it can be a mediator in associations between the above listed RTIs and fibroids, thus precluding it’s inclusion in a 
model with them 
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Supplemental Table 2. Percent Distributions of Covariates by Self-Reported Reproductive Tract Infection Status 
 
 
PID Chlamydia 
Bacterial 
Vaginosis 
 
Trichomonas 
 
Gonorrhea 
Genital 
Herpes 
Genital 
Warts 
Covariate  
Yes 
n = 162 
% 
Yes 
n = 628 
% 
Yes 
n = 624 
% 
Yes 
n = 530 
% 
Yes 
n = 323 
% 
Yes 
n = 143 
% 
Yes 
n = 113 
% 
Age (years)        
    23-26  24  33 28 25 29 26 20 
    27-30  41  33 35 34 36 34 37 
    ≥31  36 34 37 41 35 40 43 
Education         
    ≤ High        
    school/GED 
27 19   15 20 25 18 16 
    Some college  
    or technical 
56 57 54 58 56 47 49 
    ≥ Bachelors 17 24 31 22 19 36 35 
BMI (kg/m
2
)        
    15-24 20 18 20 14 21 15 18 
    25-29 20 25 25 19 25 33 24 
    30-34 18 20 22 20 20 21 26 
    ≥ 35 43  37 33 47 35 32 33 
Alcohol at age when 
drinking the most
a
 
       
    Low 21 21  18 17 20 18 18 
    Moderate 22 31 36 30 31 41 36 
    Heavy 57 48 46 53 50 41 46 
Parity        
    Nulliparous 30 33 36 32 30 43 40 
    Parous  70 68 64 68 70 57 60 
Depo-Provera        
    Never used 48 52 56 50 46 52 53 
    Ever used 52 48 44 50 54  48 47 
Age at menarche (years)        
    7-10  22 19 17 20 18 20 15 
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PID Chlamydia 
Bacterial 
Vaginosis 
 
Trichomonas 
 
Gonorrhea 
Genital 
Herpes 
Genital 
Warts 
Covariate  
Yes 
n = 162 
% 
Yes 
n = 628 
% 
Yes 
n = 624 
% 
Yes 
n = 530 
% 
Yes 
n = 323 
% 
Yes 
n = 143 
% 
Yes 
n = 113 
% 
    11-19  78 81 83 80 82 80 85 
Sex partners before age 20         
    ≤1    14   12 17 13   12 16 17 
    2-5 49  48 49 50 43 51 42 
    ≥ 6   38 40 34 38 45 33 42 
Age at 1
st
 sex (years)        
   ≤14 43 38 35 41 42 40 33 
   15-16 32 38 37 34 36 25 34 
    ≥ 17  25 24 28 25 23 35 34 
 
BMI, body mass index; GED, general education degree; IQR, interquartile range; PID, pelvic inflammatory disease 
a
Low drinkers were those who never had 10 or more drinks in a year. Heavy drinkers were those who usually drank 6 or more drinks on 
days when they drank or drank 4 or more drinks per sitting at least 2 to 3 times a month. Moderate drinkers were all others. 
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Supplemental Table 3. Years since First Diagnosis of Reproductive Tract Infections 
 
Reproductive Tract 
Infection 
Fibroids Total 
Yes No  
Median Years (IQR) Median Years (IQR) 
Any RTI
a
 10 (6-14) 8 (5-12) 9 (5-13) 
PID  8.5 (5-12) 7 (4-12) 7 (4-12) 
Chlamydia 11 (7-14) 8 (5-12) 9 (5-13) 
Bacterial Vaginosis 6 (3-10) 6 (3-9) 6 (3-10) 
Trichomonas 8 (3-12) 7 (4-11) 7 (4-11) 
Gonorrhea 12 (8-15) 8.5 (5-12) 9 (6-13) 
Genital Herpes 7 (5-12) 5 (2-9) 6 (2-10) 
Genital Warts 6 (2-11.5) 10 (6-12.5) 10 (6-13) 
 
 
IQR, interquartile range; PID, pelvic inflammatory disease; RTI, reproductive tract infection 
 a
Includes pelvic inflammatory disease, chlamydia, bacterial vaginosis, trichomonas, gonorrhea, genital herpes    
 and genital warts 
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Supplemental Table 4. Adjusted Odds Ratios for Fibroids According to Self-Reported 
History of Number of Different Reproductive Tract Infections and Number of Diagnoses for 
Each Infection 
 
 
Fibroids Age-adjusted 
Multivariable-
adjusted
a
 
Reproductive Tract 
Infections  
 
Yes 
n = 363 
n (%)
a
 
No 
n = 1,293 
n (%) 
OR (95% CI) OR (95% CI) 
Number of     
Different RTIs 
Reported     
0 101 (28) 381 (30) 1 (ref) 1 (ref) 
1 103 (28) 350 (27) 1.08 (0.79-1.49)        1.19 (0.86-1.64) 
2 85 (23) 238 (18) 1.32 (0.94-1.85)        1.41 (0.99-2.01) 
3+ 74 (20) 320 (25) 0.82 (0.58-1.15)         0.91 (0.63-1.30)         
Missing  4   
PID     
    Diagnoses (n)     
0 329 (91) 1,164 (90) 1 (ref) 1 (ref) 
1 28 (8) 104 (8) 0.94 (0.60-1.47) 0.98 (0.62-1.55) 
2+ 6 (2) 24 (2) 0.75 (0.30-1.88) 0.79 (0.31-2.02) 
Missing  1   
Chlamydia     
    Diagnoses (n)     
0 238 (66) 788 (61) 1 (ref) 1 (ref) 
1 80 (22) 339 (26) 0.82 (0.61-1.09) 0.86 (0.64-1.16) 
2+ 45 (12) 164 (13) 0.92 (0.63-1.32) 1.02 (0.70-1.50) 
Missing  2   
Bacterial Vaginosis     
     Diagnoses (n)     
0 216 (60) 815 (63) 1 (ref) 1 (ref) 
1 50 (14) 164 (13) 1.22 (0.85-1.74) 1.23 (0.85-1.78) 
2+ 97 (27) 313 (24) 1.10 (0.83-1.45) 1.11 (0.83-1.49) 
Missing  1   
Trichomonas     
    Diagnoses (n)     
0 247 (68) 878 (68) 1 (ref) 1 (ref) 
1 76 (21) 276 (21) 0.91 (0.68-1.23) 0.93 (0.68-1.27) 
2+ 40 (11) 138 (11) 0.88 (0.60-1.30) 0.90 (0.60-1.35) 
Missing  1   
Gonorrhea     
     Diagnoses (n)     
0 301 (83) 1,031 (78) 1 (ref) 1 (ref) 
1 41 (11) 190 (15) 0.74 (0.51-1.07) 0.81 (0.56-1.19) 
2+ 21 (6) 71 (6) 1.01 (0.61-1.69) 1.21 (0.71-2.04) 
Missing  1   
 
CI, confidence interval; OR, odds ratio; PID, pelvic inflammatory disease; RTI, reproductive tract infection  
a
Logistic regression model adjusted for age (continuous), education, body mass index, alcohol, menarche, 
parity, and Depo-Provera use 
Genital herpes was not included because the number of times diagnosed was not applicable; 
Genital warts was not included because only 9 participants were diagnosed more than once   
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